Lisa Butler

Research Interests

Cancer Cell Biology Cancer Therapy Cancer Biology and Clinical Oncology Nutrition and Metabolic Health Innovative Therapeutics Men's Health

Prof Lisa Butler

Program Leader

SAIGENCI

College of Health

Eligible to supervise Masters and PhD - email supervisor to discuss availability.

Professor Lisa Butler is a full-time academic researcher at the South Australian Immunogenomics Cancer Institute (SAiGENCI) and the Freemasons Centre for Male Health and Wellbeing (FCMHW) at the University of Adelaide. She is a Program Lead for Resistance Prevention at SAiGENCI and Director of the Solid Tumour Program at the South Australian Health and Medical Research Institute (SAHMRI). Prof Butler holds key executive positions in the Australian Prostate Cancer BioResource, the Prostate Cancer Foundation of Australia and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group.

Prof Butler has established an internationally-recognised research program focused on targeting androgen signalling in prostate cancer, discovering innovative biomarkers of response to treatment, and testing the efficacy of novel drugs for prostate cancer.

Prof Butler undertook postdoctoral studies at Memorial Sloan-Kettering Cancer Center in New York from 1998-2001. Her work there directly contributed to the clinical development of histone deacetylase inhibitors as anticancer agents and formed the basis of her interests in translational research. Since returning to Australia, a major focus of her research program has been the development of preclinical models that more closely represent the individual responses in men with prostate cancer. She developed the unique ex vivo tumor culture model, which has been applied to multiple tissues and resulted in the adoption of the technique by scientists from the University of Leuven, Belgium, Thomas Jefferson University, Philadelphia, UT Southwestern, Dallas and the Royal Marsden Hospital, London. Prof Butler’s research group has used this model to demonstrate the anti-proliferative efficacy of the novel heat shock protein 90 inhibitor AUY922 and the cyclin dependent kinase inhibitor ribociclib in prostate cancer tissues (Clin Cancer Res 18:3562), and funding was subsequently awarded by Cancer Australia in 2013 to translate these preclinical studies into an ongoing clinical trial of ribociclib for prostate cancer. From 2015-21 she led a Movember Revolutionary Team to investigate the role of lipids in prostate cancer and their potential for new biomarkers of disease aggressiveness, and in 2019 she and her collaborators were awarded funding from the US Department of Defense to further study the role of lipid metabolising enzymes in prostate cancer. Her other major research interests include development of novel combinatorial strategies to target the androgen receptor and lipid metabolism pathways in prostate cancer.

Date Position Institution name
2024 - ongoing Program Lead, Resistance Prevention University of Adelaide
2022 - 2026 Head, Prostate Cancer Research Group University of Adelaide
2022 - ongoing Director, Solid Tumour Program South Australian Health and Medical Research Institute
2018 - 2022 Cancer Council Principal Research Fellow University of Adelaide
2014 - 2018 Australian Research Council Future Fellow University of Adelaide
2012 - 2013 University Senior Research Fellow University of Adelaide
2008 - 2012 Cancer Council SA Senior Research Fellow University of Adelaide
2006 - 2008 Florey Research Fellow University of Adelaide
2003 - 2005 Prostate Cancer Foundation of Australia Research Fellow University of Adelaide
2002 - 2002 NHMRC Senior Research Officer University of Adelaide
2001 - 2001 NHMRC Senior Research Officer Flinders University

Date Type Title Institution Name Country Amount
2021 Award Women in Leadership Award Cancer Council SA Beat Cancer Project Australia $60,000
2011 Nomination Nominated Delegate, NHMRC 75th Anniversary Symposium National Health and Medical Research Council Australia -
2004 Honour The Governor’s Leadership Foundation of South Australia The Governor’s Leadership Foundation of South Australia Australia -
2003 Award ILEX Oncology Scholar-in-Training Award American Association for Cancer Research United States -
2002 Award Bio-Rad New Investigator Award Australian Society for Medical Research Australia -
2001 Award Gerald B. Grindey Scholar In Training Award American Association for Cancer Research United States -
1997 Award AMRAD Young Investigator Award Australian Society for Medical Research Australia -
1996 Award The Ross Wishart Memorial Award Australian Society for Medical Research Australia -
1994 Award The R.F. Whelan Prize The Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists Australia -
1994 Award Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists Prize The University of Adelaide Australia -

Date Institution name Country Title
1995 - 1998 University of Adelaide Australia PhD
1994 - 1994 University of Adelaide Australia BSC (Hons)
1991 - 1993 University of Adelaide Australia BSc

Date Title Institution Country
1998 - 2001 Postdoctoral Fellow Memorial Sloan Kettering Cancer Center, New York United States

Year Citation
2026 Portman, N., Mak, B., Yeung, N., Lin, H. M., Kim, R. M. N., Mellor, R., . . . Horvath, L. G. (2026). Characterising the effect of circulating sphingolipids on metastatic prostate cancer cells. Ebiomedicine, 123, 12 pages.
DOI
2025 Heatlie, J. K., Lazniewska, J., Moore, C. R., Johnson, I. R. D., Nturubika, B. D., Williams, R., . . . Brooks, D. A. (2025). Extracellular Vesicles and Tunnelling Nanotubes as Mediators of Prostate Cancer Intercellular Communication. Biomolecules, 15(1), 23.
DOI Scopus5 WoS5 Europe PMC3
2025 Idkowiak, J., Dehairs, J., Schwarzerová, J., Olešová, D., Truong, J. X. M., Kvasnička, A., . . . Holčapek, M. (2025). Best practices and tools in R and Python for statistical processing and visualization of lipidomics and metabolomics data. Nature Communications, 16(1), 19 pages.
DOI
2025 Xie, J., Shen, K., Liang, W., Kuang, Z., Shrestha, R. K., Hanson, A. R., . . . Selth, L. A. (2025). Protein disulfide isomerases regulate androgen receptor stability and promote prostate cancer cell growth and survival. Proceedings of the National Academy of Sciences of the United States of America, 122(42), e2509222122-1-e2509222122-12.
DOI
2025 Cilento, M. A., Butler, L. M., Emmett, L., & Sweeney, C. J. (2025). Personalized intensification of treatment for hormone-sensitive prostate cancer. Nature Reviews Clinical Oncology, 16 pages.
DOI
2025 Plummer, J. T., Dezem, F. S., Cook, D. P., Park, J., Zhang, L., Liu, Y., . . . Martelotto, L. G. (2025). Standardized metrics for assessment and reproducibility of imaging-based spatial transcriptomics datasets. Nature Biotechnology, 24 pages.
DOI
2025 Hindes, M. T., McElligott, A. M., Best, O. G., Ward, M. P., Selemidis, S., Miles, M. A., . . . Brooks, D. A. (2025). Metabolic reprogramming, malignant transformation and metastasis: Lessons from chronic lymphocytic leukaemia and prostate cancer. Cancer Letters, 611(217441), 217441-1-217441-18.
DOI Scopus7 WoS7 Europe PMC8
2024 Nturubika, B. D. D., Logan, J., Johnson, I. R. D., Moore, C., Li, K. L., Tang, J., . . . Brooks, D. A. (2024). Components of the endosome-lysosome vesicular machinery as drivers of the metastatic cascade in prostate cancer. Cancers, 17(1), 1, article no. 43-31.
DOI Scopus2 WoS2 Europe PMC1
2024 Shrestha, R. K., Nassar, Z. D., Hanson, A. R., Iggo, R., Townley, S. L., Dehairs, J., . . . Selth, L. A. (2024). ACSM1 and ACSM3 regulate fatty acid metabolism to support prostate cancer growth and constrain ferroptosis. Cancer Research, 84(14), 2313-2332.
DOI Scopus26 WoS27 Europe PMC23
2024 Lin, H. -M., Yang, X., Centenera, M. M., Huynh, K., Giles, C., Dehairs, J., . . . Horvath, L. G. (2024). Circulating Lipid Profiles Associated With Resistance to Androgen Deprivation Therapy in Localized Prostate Cancer. JCO Precision Oncology, 8(8), e2400260-1-e2400260-11.
DOI Scopus8 WoS8 Europe PMC7
2024 Rahman, R., Rahaman, M. H., Hanson, A. R., Choo, N., Hassankhani, R., Islam, S., . . . Selth, L. A. (2024). CDK9 inhibition inhibits multiple oncogenic transcriptional and epigenetic pathways in prostate cancer. British Journal of Cancer, 131(6), 1092-1105.
DOI Scopus3 WoS4 Europe PMC5
2024 Logan, J. M., Martini, C., Sorvina, A., Johnson, I. R. D., Brooks, R. D., Caruso, M. C., . . . Ung, B. S. -Y. (2024). Reinterpretation of prostate cancer pathology by Appl1, Sortilin and Syndecan-1 biomarkers. Scientific data, 11(1), 852-1-852-10.
DOI Scopus3 WoS4 Europe PMC1
2024 Nturubika, B. D., Guardia, C. M., Gershlick, D. C., Logan, J. M., Martini, C., Heatlie, J. K., . . . Johnson, I. R. D. (2024). Altered expression of vesicular trafficking machinery in prostate cancer affects lysosomal dynamics and provides insight into the underlying biology and disease progression. British Journal of Cancer, 131(8), 1263-1278.
DOI Scopus2 WoS3 Europe PMC2
2024 Sardar, S., McNair, C. M., Ravindranath, L., Chand, S. N., Yuan, W., Bogdan, D., . . . Shafi, A. A. (2024). AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer. Oncogene, 43(43), 3197-3213.
DOI Scopus12 WoS11 Europe PMC12
2024 Wang, T., Roach, M. J., Harvey, K., Morlanes, J. E., Kiedik, B., Al-Eryani, G., . . . Martelotto, L. G. (2024). snPATHO-seq, a versatile FFPE single-nucleus RNA sequencing method to unlock pathology archives. Commun Biol, 7(1), 1340-1-1340-12.
DOI Scopus10 WoS11 Europe PMC13
2024 Rahman, R., Rahaman, M. H., Hanson, A. R., Choo, N., Xie, J., Townley, S. L., . . . Selth, L. A. (2024). Author Correction: CDK9 inhibition constrains multiple oncogenic transcriptional and epigenetic pathways in prostate cancer.. Br J Cancer, 131(10), 1719.
DOI WoS1 Europe PMC1
2024 Srinivasan, S., Kryza, T., Bock, N., Tse, B. W. C., Sokolowski, K. A., Janaththani, P., . . . Berndt, S. I. (2024). A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer. Nature Communications, 15(1), 9587-1-9587-21.
DOI Scopus2 WoS3 Europe PMC4
2024 Jiménez-Gracia, L., Marchese, D., Nieto, J. C., Caratù, G., Melón-Ardanaz, E., Gudiño, V., . . . Martelotto, L. G. (2024). FixNCut: single-cell genomics through reversible tissue fixation and dissociation. Genome Biology, 25(1), 81-1-81-36.
DOI Scopus6 WoS6 Europe PMC11
2024 Scott, J. S., Quek, L. -E., Hoy, A. J., Swinnen, J. V., Nassar, Z. D., & Butler, L. M. (2024). Fatty acid elongation regulates mitochondrial β-oxidation and cell viability in prostate cancer by controlling malonyl-CoA levels. Biochemical and Biophysical Research Communications, 691, 149273.
DOI Scopus3 WoS2 Europe PMC2
2024 Mah, C. Y., Nguyen, A. D. T., Niijima, T., Helm, M., Dehairs, J., Ryan, F. J., . . . Butler, L. M. (2024). Peroxisomal β-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance in advanced prostate cancer. British Journal of Cancer, 130(5), 741-754.
DOI Scopus16 WoS16 Europe PMC16
2024 Truong, J. X. M., Rao, S. R., Ryan, F. J., Lynn, D. J., Snel, M. F., Butler, L. M., & Trim, P. J. (2024). Spatial MS multiomics on clinical prostate cancer tissues.. Analytical and Bioanalytical Chemistry, 416(7), 1745-1757.
DOI Scopus8 WoS8 Europe PMC5
2024 Brennen, W. N., Le Magnen, C., Karkampouna, S., Anselmino, N., Bock, N., Choo, N., . . . Lawrence, M. G. (2024). Defining the challenges and opportunities for using patient-derived models in prostate cancer research. The Prostate, 84(7), 623-635.
DOI Scopus2 WoS2 Europe PMC2
2024 Sardar, S., McNair, C. M., Ravindranath, L., Chand, S. N., Yuan, W., Bogdan, D., . . . Shafi, A. A. (2024). AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer.. bioRxiv.
DOI
2024 Boufaied, N., Chetta, P., Hallal, T., Cacciatore, S., Lalli, D., Luthold, C., . . . Zadra, G. (2024). Obesogenic High-Fat Diet and MYC Cooperate to Promote Lactate Accumulation and Tumor Microenvironment Remodeling in Prostate Cancer.. Cancer Res, 84(11), 1834-1855.
DOI Scopus22 WoS25 Europe PMC18
2024 Cilento, M. A., Sweeney, C. J., & Butler, L. M. (2024). Spatial transcriptomics in cancer research and potential clinical impact: a narrative review. Journal of Cancer Research and Clinical Oncology, 150(6), 296-1-296-16.
DOI Scopus21 WoS21 Europe PMC21
2023 Martini, C., Logan, J. M., Sorvina, A., Gordon, C., Beck, A. R., S-Y Ung, B., . . . Brooks, D. A. (2023). Aberrant protein expression of Appl1, Sortilin and Syndecan-1 during the biological progression of prostate cancer. Pathology, 55(1), 40-51.
DOI Scopus19 WoS20 Europe PMC18
2023 Shin, S. Y., Centenera, M. M., Hodgson, J. T., Nguyen, E. V., Butler, L. M., Daly, R. J., & Nguyen, L. K. (2023). A Boolean-based machine learning framework identifies predictive biomarkers of HSP90-targeted therapy response in prostate cancer. Frontiers in Molecular Biosciences, 10, 1094321-1-1094321-16.
DOI Scopus7 WoS6 Europe PMC5
2023 Scheinberg, T., Mak, B., Butler, L., Selth, L., & Horvath, L. G. (2023). Targeting lipid metabolism in metastatic prostate cancer. Therapeutic Advances in Medical Oncology, 15, 1-30.
DOI Scopus29 WoS27 Europe PMC26
2023 Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (2023). Supplementary Tables S2-S6 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition.
DOI
2023 Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (2023). Supplementary Table S1 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition.
DOI
2023 Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (2023). Table S2 from Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition.
DOI
2023 Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (2023). Table S1 from Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition.
DOI
2023 Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (2023). Supplementary Figures and Legends 1-8 from Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition.
DOI
2023 Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (2023). Supplementary Figures S1-S6 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition.
DOI
2023 Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (2023). Table S2 from Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition.
DOI
2023 Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (2023). Supplementary Figures S1-S6 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition.
DOI
2023 Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (2023). Data from Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition.
DOI
2023 Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (2023). Data from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition.
DOI
2023 Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (2023). Table S1 from Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition.
DOI
2023 Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (2023). Table S3 from Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition.
DOI
2023 Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (2023). Table S3 from Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition.
DOI
2023 Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (2023). Data from Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition.
DOI
2023 Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (2023). Supplementary Tables S2-S6 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition.
DOI
2023 Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (2023). Table S4 from Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition.
DOI
2023 Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (2023). Table S4 from Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition.
DOI
2023 Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S. M., . . . Swinnen, J. V. (2023). Supplementary Table S1 from Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition.
DOI
2023 Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (2023). Supplementary Figures and Legends 1-8 from Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition.
DOI
2023 Centenera, M. M., Scott, J. S., Machiels, J., Nassar, Z. D., Miller, D. C., Zinonos, I., . . . Butler, L. M. (2023). Data from ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer.
DOI
2023 Centenera, M. M., Scott, J. S., Machiels, J., Nassar, Z. D., Miller, D. C., Zinonos, I., . . . Butler, L. M. (2023). Supplementary Data from ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer.
DOI
2023 Centenera, M. M., Scott, J. S., Machiels, J., Nassar, Z. D., Miller, D. C., Zinonos, I., . . . Butler, L. M. (2023). Supplementary Data from ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer.
DOI
2023 Balaban, S., Nassar, Z. D., Zhang, A. Y., Hosseini-Beheshti, E., Centenera, M. M., Schreuder, M., . . . Hoy, A. J. (2023). Data from Extracellular Fatty Acids Are the Major Contributor to Lipid Synthesis in Prostate Cancer.
DOI
2023 Balaban, S., Nassar, Z. D., Zhang, A. Y., Hosseini-Beheshti, E., Centenera, M. M., Schreuder, M., . . . Hoy, A. J. (2023). Supplementary Figures 1-3 from Extracellular Fatty Acids Are the Major Contributor to Lipid Synthesis in Prostate Cancer.
DOI
2023 Balaban, S., Nassar, Z. D., Zhang, A. Y., Hosseini-Beheshti, E., Centenera, M. M., Schreuder, M., . . . Hoy, A. J. (2023). Supplementary Figures 1-3 from Extracellular Fatty Acids Are the Major Contributor to Lipid Synthesis in Prostate Cancer.
DOI
2023 Logan, J. M., Hopkins, A. M., Martini, C., Sorvina, A., Tewari, P., Prabhakaran, S., . . . Brooks, D. A. (2023). Prediction of Prostate Cancer Biochemical and Clinical Recurrence Is Improved by IHC-Assisted Grading Using Appl1, Sortilin and Syndecan-1.. Cancers, 15(12), 1-12.
DOI Scopus10 WoS9 Europe PMC7
2023 Menzel, J. P., Young, R. S. E., Benfield, A. H., Scott, J. S., Wongsomboon, P., Cudlman, L., . . . Blanksby, S. J. (2023). Ozone-enabled fatty acid discovery reveals unexpected diversity in the human lipidome. Nature Communications, 14(1), 1-16.
DOI Scopus38 WoS37 Europe PMC31
2023 Butler, L. M., & Evergren, E. (2023). Ultrastructural analysis of prostate cancer tissue provides insights into androgen-dependent adaptations to membrane contact site establishment. Frontiers in Oncology, 13, 1217741-1-1217741-13.
DOI Scopus2 WoS1 Europe PMC1
2023 Lazniewska, J., Li, K. L., Johnson, I. R. D., Sorvina, A., Logan, J. M., Martini, C., . . . Brooks, D. A. (2023). Dynamic interplay between sortilin and syndecan-1 contributes to prostate cancer progression. Scientific reports, 13(1, article no. 13489), 1-18.
DOI Scopus13 WoS14 Europe PMC10
2023 Hinneh, J. A., Gillis, J. L., Mah, C. Y., Irani, S., Shrestha, R. K., Ryan, N. K., . . . Butler, L. M. (2023). Targeting hyaluronan-mediated motility receptor (HMMR) enhances response to androgen receptor signalling inhibitors in prostate cancer. British Journal of Cancer, 129(8), 1350-1361.
DOI Scopus11 WoS12 Europe PMC11
2022 A, M., Owen, K. L., Townley, S., Zanker, D., Rollin, S. P. G., Hanson, A. R., . . . Selth, L. A. (2022). Potent Stimulation of the Androgen Receptor Instigates a Viral Mimicry Response in Prostate Cancer. Cancer research communications, 2(7), 706-724.
DOI Scopus12 WoS12 Europe PMC9
2022 Scott, J. S., Nassar, Z. D., Swinnen, J. V., & Butler, L. M. (2022). Monounsaturated fatty acids: key regulators of cell viability and intracellular signalling in cancer.. Mol Cancer Res, 20(9), 1354-1364.
DOI Scopus29 WoS29 Europe PMC30
2022 Linder, S., Hoogstraat, M., Stelloo, S., Eickhoff, N., Schuurman, K., de Barros, H., . . . Zwart, W. (2022). Drug-induced epigenomic plasticity reprograms circadian rhythm regulation to drive prostate cancer towards androgen-independence.. Cancer Discovery, 12(9), 2074-2097.
DOI Scopus63 WoS65 Europe PMC62
2022 Hinneh, J. A., Gillis, J. L., Moore, N. L., Butler, L. M., & Centenera, M. M. (2022). The role of RHAMM in cancer: Exposing novel therapeutic vulnerabilities. Frontiers in Oncology, 12, 1-14.
DOI Scopus26 WoS25 Europe PMC25
2022 Kobayashi, H., Gieniec, K. A., Lannagan, T. R., Wang, T., Asai, N., Mizutani, Y., . . . Worthley, D. L. (2022). The origin and contribution of cancer-associated fibroblasts in colorectal carcinogenesis. Gastroenterology, 162(3), 890-906.
DOI Scopus145 WoS156 Europe PMC135
2022 Raftopulos, N. L., Washaya, T. C., Niederprum, A., Egert, A., Hakeem-Sanni, M. F., Varney, B., . . . Hoy, A. J. (2022). Prostate cancer cell proliferation is influenced by LDL-cholesterol availability and cholesteryl ester turnover. Cancer & Metabolism, 10(1), 1-15.
DOI WoS33 Europe PMC34
2022 Dylgjeri, E., Kothari, V., Shafi, A. A., Semenova, G., Gallagher, P. T., Guan, Y. F., . . . Knudsen, K. E. (2022). A Novel Role for DNA-PK in Metabolism by Regulating Glycolysis in Castration Resistant Prostate Cancer. Clinical Cancer Research, 28(7), 1446-1459.
DOI Scopus21 WoS21 Europe PMC20
2022 Mak, B., Lin, H. -M., Kwan, E. M., Fettke, H., Tran, B., Davis, I. D., . . . Horvath, L. G. (2022). Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer. BMC Medicine, 20(1), 112-1-112-14.
DOI Scopus16 WoS18 Europe PMC18
2022 Mutuku, S. M., Spotbeen, X., Trim, P. J., Snel, M. F., Butler, L. M., & Swinnen, J. V. (2022). Unravelling Prostate Cancer Heterogeneity Using Spatial Approaches to Lipidomics and Transcriptomics. Cancers, 14(7), 1-16.
DOI Scopus18 WoS18 Europe PMC17
2022 Centenera, M. M., Vincent, A. D., Moldovan, M., Lin, H. M., Lynn, D. J., Horvath, L. G., & Butler, L. M. (2022). Harnessing the Heterogeneity of Prostate Cancer for Target Discovery Using Patient-Derived Explants. Cancers, 14(7), 1-18.
DOI Scopus13 WoS12 Europe PMC15
2022 Mak, B., Lin, H. -M., Duong, T., Mahon, K. L., Joshua, A. M., Stockler, M. R., . . . Horvath, L. G. (2022). Modulation of Plasma Lipidomic Profiles in Metastatic Castration-Resistant Prostate Cancer by Simvastatin. Cancers, 14(19), 1-15.
DOI Scopus9 WoS9 Europe PMC9
2022 Menzel, J. P., Young, R. S. E., Benfield, A. H., Scott, J., Butler, L. M., Henriques, S. T., . . . Blanksby, S. J. (2022). OzFAD: Ozone-enabled fatty acid discovery reveals unexpected diversity in the human lipidome.
DOI
2021 Allen, J. A., Butler, L., Levine, T., & Haudrich, A. (2021). A Global Survey of Disease Burden in Patients Who Carry a Diagnosis of Chronic Inflammatory Demyelinating Polyneuropathy. ADVANCES IN THERAPY, 38(1), 316-328.
DOI WoS17
2021 Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S., . . . Swinnen, J. V. (2021). Lipidomic profiling of clinical prostate cancer reveals targetable alterations in membrane lipid composition. Cancer Research.
DOI
2021 Lin, H. M., Mak, B., Yeung, N., Huynh, K., Meikle, T. G., Mellett, N. A., . . . Horvath, L. G. (2021). Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase. EBioMedicine, 72, 103625-1-103625-15.
DOI Scopus39 WoS40 Europe PMC36
2021 Tieu, T., Irani, S., Bremert, K. L., Ryan, N. K., Wojnilowicz, M., Helm, M., . . . Cifuentes-Rius, A. (2021). Patient-derived prostate cancer explants: a clinically relevant model to assess siRNA-based nanomedicines. Advanced Healthcare Materials, 10(6), 2001594-1-2001594-11.
DOI Scopus18 WoS18 Europe PMC13
2021 Kwan, K. H., Burvenich, I. J. G., Centenera, M. M., Goh, Y. W., Rigopoulos, A., Dehairs, J., . . . Ackermann, U. (2021). Synthesis and fluorine-18 radiolabeling of a phospholipid as a PET imaging agent for prostate cancer. Nuclear medicine and biology, 93, 37-45.
DOI Scopus4 WoS3 Europe PMC3
2021 Lin, H. -M., Huynh, K., Kohli, M., Tan, W., Azad, A. A., Yeung, N., . . . Horvath, L. G. (2021). Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer. Prostate Cancer and Prostatic Diseases, 24(3), 860-870.
DOI Scopus24 WoS26 Europe PMC24
2021 Gillis, J. L., Hinneh, J. A., Ryan, N. K., Irani, S., Moldovan, M., Quek, L. -E., . . . Butler, L. M. (2021). A feedback loop between the androgen receptor and 6-phosphogluoconate dehydrogenase (6PGD) drives prostate cancer growth. eLife, 10, e62592-1-e62592-27.
DOI Scopus27 WoS28 Europe PMC31
2021 Hoy, A. J., Nagarajan, S. R., & Butler, L. M. (2021). Tumour fatty acid metabolism in the context of therapy resistance and obesity. Nature Reviews Cancer, 21(12), 753-766.
DOI Scopus295 WoS292 Europe PMC283
2021 Fernandes, R. C., Toubia, J., Townley, S., Hanson, A. R., Dredge, B. K., Pillman, K. A., . . . Selth, L. A. (2021). Post-transcriptional gene regulation by microRNA-194 promotes neuroendocrine transdifferentiation in prostate cancer. Cell Reports, 34(1), 1-17.
DOI Scopus41 WoS41 Europe PMC42
2021 Nagarajan, S. R., Butler, L. M., & Hoy, A. J. (2021). The diversity and breadth of cancer cell fatty acid metabolism. Cancer & Metabolism, 9(1), 1-28.
DOI WoS138 Europe PMC138
2021 Kokkinos, J., Sharbeen, G., Haghighi, K. S., Ignacio, R. M. C., Kopecky, C., Gonzales-Aloy, E., . . . Phillips, P. A. (2021). Ex vivo culture of intact human patient derived pancreatic tumour tissue. Scientific Reports, 11(1), 1-15.
DOI Scopus55 WoS52 Europe PMC49
2021 Butler, L. M., Mah, C. Y., Machiels, J., Vincent, A. D., Irani, S., Mutuku, S., . . . Swinnen, J. V. (2021). Lipidomic profiling of clinical prostate cancer reveals targetable alterations in membrane lipid composition. Cancer Research, 81(19), 4981-4993.
DOI Scopus63 WoS62 Europe PMC59
2021 Centenera, M. M., Scott, J. S., Machiels, J., Nassar, Z. D., Miller, D. C., Zinonos, I., . . . Butler, L. M. (2021). ELOVL5 is a critical and targetable fatty acid elongase in prostate cancer. Cancer Research, 81(7), 1704-1718.
DOI Scopus71 WoS68 Europe PMC70
2021 Truong, J. X. M., Spotbeen, X., White, J., Swinnen, J. V., Butler, L. M., Snel, M. F., & Trim, P. J. (2021). Removal of optimal cutting temperature (O.C.T.) compound from embedded tissue for MALDI imaging of lipids.. Anal Bioanal Chem, 413(10), 2695-2708.
DOI Scopus30 WoS27 Europe PMC26
2020 Kobayashi, H., Gieniec, K. A., Wright, J. A., Wang, T., Asai, N., Mizutani, Y., . . . Woods, S. L. (2020). The Balance of stromal BMP signaling mediated by GREM1 and ISLR drives colorectal carcinogenesis. Gastroenterology, 160(4), 1224-1239.
DOI Scopus122 WoS119 Europe PMC123
2020 Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., . . . Butler, L. M. (2020). Fatty acid oxidation is an adaptive survival pathway induced in prostate tumors by heat shock protein 90 inhibition. Molecular cancer research : MCR, 18(10), 1500-1511.
DOI Scopus19 WoS18 Europe PMC19
2020 Nassar, Z. D., Mah, C. Y., Dehairs, J., Burvenich, I. J., Irani, S., Centenera, M. M., . . . Butler, L. M. (2020). Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis. Elife, 9, 1-34.
DOI Scopus151 WoS148 Europe PMC150
2020 Butler, L., Perone, Y., Dehairs, J., Lupien, L. E., de Laat, V., Talebi, A., . . . Swinnen, J. V. (2020). Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention.. Advanced Drug Delivery Reviews, 159, 245-293.
DOI Scopus479 WoS458 Europe PMC416
2020 Hollis, B., Day, F. R., Busch, A. S., Thompson, D. J., Soares, A. L. G., Timmers, P. R. H. J., . . . Butler, L. (2020). Genomic analysis of male puberty timing highlights shared genetic basis with hair colour and lifespan. Nature Communications, 11(1), 1536-1-1536-10.
DOI Scopus51 Europe PMC49
2020 Wu, Y., Xie, J., Xin, J., Lenchine, R. V., Wang, X., Fang, M. D., . . . Proud, C. G. (2020). eEF2K enhances expression of PD-L1 by promoting the translation of its mRNA. Biochemical Journal, 477(22), 4367-4381.
DOI Scopus32 WoS34 Europe PMC30
2020 Scheinberg, T., Kench, J., Stockler, M., Mahon, K. L., Sebastian, L., Stricker, P., . . . Horvath, L. G. (2020). Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer). BMJ Open, 10(1), e033667-1-e033667-6.
DOI Scopus14 WoS13 Europe PMC12
2020 Jankovic-Karasoulos, T., Bianco-Miotto, T., Butler, M. S., Butler, L. M., McNeil, C. M., O'Toole, S. A., . . . Ricciardelli, C. (2020). Elevated levels of tumor apolipoprotein D independently predict poor outcome in breast cancer patients. Histopathology, 76(7), 976-987.
DOI Scopus32 WoS29 Europe PMC29
2020 Mah, C. Y., Nassar, Z. D., Swinnen, J. V., & Butler, L. M. (2020). Lipogenic effects of androgen signaling in normal and malignant prostate. Asian Journal of Urology, 7(3), 258-270.
DOI Scopus37 WoS35 Europe PMC37
2020 Xie, J., Shen, K., Jones, A. T., Yang, J., Tee, A. R., Shen, M. H., . . . Proud, C. G. (2020). Reciprocal signaling between mTORC1 and MNK2 controls cell growth and oncogenesis.. Cellular and molecular life sciences : CMLS, 78(1), 249-270.
DOI Scopus18 WoS21 Europe PMC16
2020 Owen, K. L., Gearing, L. J., Zanker, D. J., Brockwell, N. K., Khoo, W. H., Roden, D. L., . . . Parker, B. S. (2020). Prostate cancer cell-intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone. EMBO Reports, 21(6), e50162-1-e50162-24.
DOI Scopus72 WoS72 Europe PMC75
2020 Shirazi, H. S., Chan, K. M., Rouget, J., Ostrikov, K., McNicholas, K., Li, J., . . . MacGregor, M. (2020). Plasma enabled devices for the selective capture and photodynamic identification of prostate cancer cells.. Biointerphases, 15(3), 031002.
DOI Scopus11 WoS10 Europe PMC8
2020 Miladinovic, D., Cusick, T., Mahon, K. L., Haynes, A. -M., Cortie, C. H., Meyer, B. J., . . . Hoy, A. J. (2020). Assessment of Periprostatic and Subcutaneous Adipose Tissue Lipolysis and Adipocyte Size from Men with Localized Prostate Cancer. Cancers, 12(6), 1385-1-1385-19.
DOI Scopus14 WoS15 Europe PMC13
2020 Zadra, G., Ribeiro, C. F., Chetta, P., Cacciatore, S., Gao, X., Syamala, S., . . . Loda, M. (2020). Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer (vol 116, pg 631, 2018). PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 117(31), 18893.
DOI
2019 Johnson, I. R. D., Sorvina, A., Logan, J. M., Moore, C. R., Heatlie, J. K., Parkinson-Lawrence, E. J., . . . Brooks, D. A. (2019). A paradigm in immunochemistry, revealed by monoclonal antibodies to spatially distinct epitopes on Syntenin-1. International Journal of Molecular Sciences, 20(23), 6035-1-6035-16.
DOI Scopus7 WoS7 Europe PMC5
2019 Nassar, Z., Mah, C. Y., Dehairs, J., Burvenich, I. J. G., Irani, S., Centenera, M., . . . Butler, L. (2019). DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis.
DOI
2019 Balaban, S., Nassar, Z. D., Zhang, A. Y., Hosseini-Beheshti, E., Centenera, M. M., Schreuder, M., . . . Hoy, A. J. (2019). Extracellular fatty acids are the major contributor to lipid synthesis in prostate cancer. Molecular Cancer Research, 17(4), 949-962.
DOI Scopus68 WoS67 Europe PMC68
2019 Zadra, G., Ribeiro, C. F., Chetta, P., Ho, Y., Cacciatore, S., Gao, X., . . . Loda, M. (2019). Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 116(2), 631-640.
DOI Scopus217 WoS218 Europe PMC215
2019 Matejcic, M., Saunders, E. J., Dadaev, T., Brook, M. N., Wang, K., Sheng, X., . . . Ranu, H. (2019). Erratum to: Germline variation at 8q24 and prostate cancer risk in men of European ancestry (Nature Communications, (2018), 9, 1, (4616), 10.1038/s41467-018-06863-1). Nature Communications, 10(1), 5 pages.
DOI Scopus1 WoS1 Europe PMC1
2019 Zhang, A. Y., Chiam, K., Haupt, Y., Fox, S., Birch, S., Tilley, W., . . . Kench, J. G. (2019). An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy. International Journal of Cancer, 144(5), 1151-1159.
DOI Scopus14 WoS15 Europe PMC13
2019 Mutuku, S. M., Trim, P. J., Prabhala, B. K., Irani, S., Bremert, K. L., Logan, J. M., . . . Butler, L. M. (2019). Evaluation of small molecule drug uptake in patient-derived prostate cancer explants by mass spectrometry. Scientific Reports, 9(1), 15008.
DOI Scopus14 WoS13 Europe PMC12
2019 Irani, Y. D., Pulford, E., Mortimer, L., Irani, S., Butler, L., Klebe, S., & Williams, K. A. (2019). Sex differences in corneal neovascularization in response to superficial corneal cautery in the rat. PLoS ONE, 14(9), e0221566-1-e0221566-17.
DOI Scopus7 WoS7 Europe PMC6
2019 Tieu, T., Dhawan, S., Haridas, V., Butler, L. M., Thissen, H., Cifuentes-Rius, A., & Voelcker, N. H. (2019). Maximizing RNA loading for gene silencing using porous silicon nanoparticles. ACS Applied Materials and Interfaces, 11(26), 22993-23005.
DOI Scopus33 WoS29 Europe PMC17
2019 Gieniec, K. A., Butler, L. M., Worthley, D. L., & Woods, S. L. (2019). Cancer-associated fibroblasts—heroes or villains?. British Journal of Cancer, 121(4), 293-302.
DOI Scopus180 WoS172 Europe PMC166
2018 McClurg, U. L., McCracken, S. R., Butler, L., Riabowol, K. T., & Binda, O. (2018). Ex vivo culture and lentiviral transduction of Benign Prostatic Hyperplasia (BPH) samples. Bio-protocols, 8(21), e3075-.
DOI WoS2 Europe PMC2
2018 Matejcic, M., Saunders, E. J., Dadaev, T., Brook, M. N., Wang, K., Sheng, X., . . . Butler, L. (2018). Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nature Communications, 9(1), 4616-1-4616-11.
DOI Scopus47 WoS45 Europe PMC45
2018 Nguyen, E., Centenera, M., Moldovan, M., Das, R., Irani, S., Vincent, A., . . . Butler, L. (2018). Identification of novel response and predictive biomarkers to Hsp90 inhibitors through mass spectrometry-based proteomic profiling of patient-derived prostate tumor explants. Molecular & cellular proteomics : MCP, 17(8), 1470-1486.
DOI Scopus29 WoS31 Europe PMC29
2018 Dadaev, T., Saunders, E., Newcombe, P., Anokian, E., Leongamornlert, D., Brook, M., . . . Sellers, T. (2018). Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nature Communications, 9(1), 19 pages.
DOI Scopus84 WoS80 Europe PMC88
2018 Aref, A., Vincent, A. D., O'Callaghan, M., Martin, S., Sutherland, P., Hoy, A., . . . Wittert, G. (2018). The inverse relationship between prostate specific antigen (PSA) and obesity. Endocrine-Related Cancer, 25(11), 933-941.
DOI Scopus23 WoS20 Europe PMC19
2018 Shafi, A., Schiewer, M., de Leeuw, R., Dlygeri, E., McCue, P., Shah, N., . . . Knudsen, K. (2018). Novel patient derived models reveal the impact of the tumor microenvironment on therapeutic response. European Urology Oncology, 1(4), 325-337.
DOI Scopus39 WoS41 Europe PMC42
2018 Centenera, M. M., Hickey, T. E., Jindal, S., Ryan, N. K., Ravindranathan, P., Mohammed, H., . . . Tilley, W. D. (2018). A patient-derived explant (PDE) model of hormone-dependent cancer. Molecular Oncology, 12(9), 1608-1622.
DOI Scopus101 WoS99 Europe PMC99
2018 Su, Y. W., Chim, S. M., Zhou, L., Hassanshahi, M., Chung, R., Fan, C., . . . Xian, C. J. (2018). Osteoblast derived-neurotrophin‑3 induces cartilage removal proteases and osteoclast-mediated function at injured growth plate in rats. Bone, 116, 232-247.
DOI Scopus18 WoS17 Europe PMC13
2018 Lin, H., Lee, B., Castillo, L., Spielman, C., Grogan, J., Yeung, N., . . . Daly, R. (2018). Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer. The Prostate, 78(4), 308-317.
DOI Scopus59 WoS60 Europe PMC53
2018 Armstrong, H., Gillis, J., Johnson, I., Nassar, Z., Moldovan, M., Levrier, C., . . . Butler, L. (2018). Dysregulated fibronectin trafficking by Hsp90 inhibition restricts prostate cancer cell invasion. Scientific reports, 8(1), 2090-1-2090-14.
DOI Scopus32 WoS32 Europe PMC30
2018 McClurg, U., Nabbi, A., Ricordel, C., Korolchuk, S., McCracken, S., Heer, R., . . . Binda, O. (2018). Human ex vivo prostate tissue model system identifies ING3 as an oncoprotein. British journal of cancer, 118(5), 713-726.
DOI Scopus26 WoS28 Europe PMC27
2018 Nassar, Z., Aref, A., Miladinovic, D., Mah, C., Raj, G., Hoy, A., & Butler, L. (2018). Peri-prostatic adipose tissue: the metabolic microenvironment of prostate cancer. BJU International, 121(Suppl. 3), 9-21.
DOI Scopus63 WoS58 Europe PMC55
2018 Cifuentes-Rius, A., Butler, L., & Voelcker, N. (2018). Precision nanomedicines for prostate cancer. Nanomedicine, 13(8), 803-807.
DOI Scopus10 WoS7 Europe PMC5
2018 Ricciardelli, C., Bianco-Miotto, T., Jindal, S., Butler, L., Leung, S., McNeil, C., . . . Tilley, W. (2018). The magnitude of androgen receptor positivity in breast cancer is critical for reliable prediction of disease outcome. Clinical Cancer Research, 24(10), 2328-2341.
DOI Scopus76 WoS71 Europe PMC69
2018 Centenera, M., Selth, L., Ebrahimie, E., Butler, L., & Tilley, W. (2018). New opportunities for targeting the androgen receptor in prostate cancer. Cold Spring Harbor Perspectives in Medicine, 10(12), 1-19.
DOI Scopus24 WoS21 Europe PMC21
2017 Das, R., Gregory, P. A., Fernandes, R. C., Denis, I., Wang, Q., Townley, S. L., . . . Selth, L. A. (2017). MicroRNA-194 promotes prostate cancer metastasis by inhibiting SOCS2. Cancer Research, 77(4), 1021-1034.
DOI Scopus103 WoS103 Europe PMC91
2017 Tran, L. N., Kichenadasse, G., Butler, L. M., Centenera, M. M., Morel, K. L., Ormsby, R. J., . . . Sykes, P. J. (2017). The combination of metformin and valproic acid induces synergistic apoptosis in the presence of p53 and androgen signaling in prostate cancer. Molecular cancer therapeutics, 16(12), 2689-2700.
DOI Scopus28 WoS27 Europe PMC19
2017 Selth, L., Das, R., Townley, S., Coutinho, I., Hanson, A., Centenera, M., . . . Tilley, W. (2017). A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer. Oncogene, 36(1), 24-34.
DOI Scopus95 WoS94 Europe PMC85
2016 Xie, J., Mølck, C., Paquet-Fifield, S., Butler, L., Sloan, E., Ventura, S., & Hollande, F. (2016). High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgenindependent prostate cancer cells. Oncotarget, 7(28), 44492-44504.
DOI Scopus18 WoS16 Europe PMC14
2016 Philp, L., Day, T., Butler, M., Laven-Law, G., Jindal, S., Hickey, T., . . . Tilley, W. (2016). Small glutamine-rich tetratricopeptide repeat-containing protein alpha (SGTA) ablation limits offspring viability and growth in mice. Scientific Reports, 6(1), 28950-1-28950-14.
DOI Scopus9 WoS9 Europe PMC9
2016 Armstrong, H., Koay, Y., Irani, S., Das, R., Nassar, Z., The Australian Prostate Cancer BioResource., . . . Butler, L. (2016). A novel class of Hsp90 C-terminal modulators have pre-clinical efficacy in prostate tumor cells without induction of a heat shock response. Prostate, 76(16), 1546-1559.
DOI Scopus23 WoS23 Europe PMC23
2016 Butler, L., Centenera, M., & Swinnen, J. (2016). Androgen control of lipid metabolism in prostate cancer: novel insights and future applications. Endocrine-Related Cancer, 23(5), 219-227.
DOI Scopus105 WoS98 Europe PMC91
2016 Carter, S., Centenera, M., Tilley, W., Selth, L., & Butler, L. (2016). IκBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor. BMC Cancer, 16(1), 141-1-141-13.
DOI Scopus12 WoS11 Europe PMC7
2016 Carter, S. L., Centenera, M. M., Tilley, W. D., Selth, L. A., & Butler, L. M. (2016). Erratum to: IΚBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor.[BMC Cancer. 2016] 16:141. Doi: 10.1186/s12885-016-2188-2.. BMC Cancer, 16(1), 1 page.
DOI Europe PMC1
2015 Johnson, I., Parkinson-Lawrence, E., Keegan, H., Spillane, C., Barry-O'Crowley, J., Watson, W., . . . Brooks, D. (2015). Endosomal gene expression: a new indicator for prostate cancer patient prognosis?. Oncotarget, 6(35), 37919-37929.
DOI Scopus40 WoS37 Europe PMC38
2015 Centenera, M., Carter, S., Gillis, J., Marrocco-Tallarigo, D., Grose, R., Tilley, W., & Butler, L. (2015). Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms. Endocrine-Related Cancer, 22(5), 805-818.
DOI Scopus26 WoS27 Europe PMC26
2015 Butler, L., Ferraldeschi, R., Armstrong, H., Centenera, M., & Workman, P. (2015). Maximizing the therapeutic potential of HSP90 inhibitors. Molecular Cancer Research, 13(11), 1445-1451.
DOI Scopus173 WoS172 Europe PMC156
2014 Johnson, I., Parkinson-Lawrence, E., Butler, L., & Brooks, D. (2014). Prostate cell lines as models for biomarker discovery: performance of current markers and the search for new biomarkers. Prostate, 74(5), 547-560.
DOI Scopus22 WoS21 Europe PMC17
2014 Johnson, I., Parkinson-Lawrence, E., Shandala, T., Weigert, R., Butler, L., & Brooks, D. (2014). Altered endosome biogenesis in prostate cancer has biomarker potential. Molecular Cancer Research, 12(12), 1851-1862.
DOI Scopus44 WoS43 Europe PMC40
2014 Selth, L. A., Roberts, M. J., Chow, C. W. K., Marshall, V. R., Doi, S. A. R., Vincent, A. D., . . . Gardiner, R. A. (2014). Human seminal fluid as a source of prostate cancer-specific microRNA biomarkers. Endocrine-Related Cancer, 21(4), L17-L21.
DOI Scopus37 WoS34 Europe PMC33
2014 Tarulli, G. A., Butler, L. M., Tilley, W. D., & Hickey, T. E. (2014). Bringing androgens up a NOTCH in breast cancer. Endocrine-Related Cancer, 21(4), T183-T202.
DOI Scopus28 WoS25 Europe PMC21
2014 Ochnik, A., Moore, N., Jankovic-Karasoulos, T., Bianco-Miotto, T., Ryan, N., Thomas, M., . . . Hickey, T. (2014). Antiandrogenic actions of medroxyprogesterone acetate on epithelial cells within normal human breast tissues cultured ex vivo. Menopause, 21(1), 79-88.
DOI Scopus18 WoS16 Europe PMC16
2014 Bianco-Miotto, T., Trotta, A., Need, E., Lee, A., Ochnik, A., Giorgio, L., . . . Buchanan, G. (2014). Molecular and structural basis of androgen receptor responses to dihydrotestosterone, medroxyprogesterone acetate and Delta(4)-tibolone. Molecular and Cellular Endocrinology, 382(2), 899-908.
DOI Scopus3 WoS1 Europe PMC2
2014 Rodrigues, D., Butler, L., Estelles, D., & de Bono, J. (2014). Molecular pathology and prostate cancer therapeutics: from biology to bedside. Journal of Pathology, 232(2), 178-184.
DOI Scopus36 WoS32 Europe PMC30
2013 Comstock, C., Augello, M., Goodwin, J., de Leeuw, R., Schiewer, M., Ostrander, W., . . . Knudsen, K. (2013). Targeting cell cycle and hormone receptor pathways in cancer. Oncogene, 32(48), 5481-5491.
DOI Scopus100 WoS89 Europe PMC86
2013 Philp, L., Butler, M., Hickey, T., Butler, L., Tilley, W., & Day, T. (2013). SGTA: A new player in the molecular co-chaperone game. Hormones and Cancer, 4(6), 343-357.
DOI Scopus29 WoS29 Europe PMC29
2013 Trotta, A., Need, E., Selth, L., Chopra, S., Pinnock, C., Leach, D., . . . Buchanan, G. (2013). Knockdown of the cochaperone SGTA results in the suppression of androgen and PI3K/Akt signaling and inhibition of prostate cancer cell proliferation. International Journal of Cancer, 133(12), 2812-2823.
DOI Scopus20 WoS19 Europe PMC20
2013 Centenera, M., Raj, G., Knudsen, K., Tilley, W., & Butler, L. (2013). Ex vivo culture of human prostate tissue and drug development. Nature Reviews, Urology, 10(8), 483-487.
DOI Scopus117 WoS113 Europe PMC110
2013 Selth, L., Townley, S., Bert, A., Stricker, P., Sutherland, P., Horvath, L., . . . Tilley, W. (2013). Circulating microRNAs predict biochemical recurrence in prostate cancer patients. British Journal of Cancer, 109(3), 641-650.
DOI Scopus117 WoS116 Europe PMC106
2013 Gillis, J., Selth, L., Centenera, M., Townley, S., Sun, S., Plymate, S., . . . Butler, L. (2013). Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors. Oncotarget, 4(5), 691-704.
DOI Scopus51 WoS50 Europe PMC44
2013 Abankwa, D., Millard, S., Martel, N., Choong, C., Yang, M., Butler, L., . . . Leong, G. (2013). Ski-interacting protein (SKIP) interacts with androgen receptor in the nucleus and modulates androgen-dependent transcription. BMC Biochemistry, 14(10), 1-9.
DOI Scopus15 WoS14 Europe PMC13
2013 Ravindranathan, P., Lee, T., Yang, L., Centenera, M., Butler, L., Tilley, W., . . . Raj, G. (2013). Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer. Nature Communications, 4(5), 1923-1-1923-11.
DOI Scopus128 WoS125 Europe PMC115
2013 Centenera, M., Fitzpatrick, A., Tilley, W., & Butler, L. (2013). Hsp90: still a viable target in prostate cancer. Biochimica et Biophysica Acta-Reviews on Cancer, 1835(2), 211-218.
DOI Scopus46 WoS43 Europe PMC36
2013 Chiam, K., Ryan, N., Ricciardelli, C., Day, T., Buchanan, G., Ochnik, A., . . . Bianco-Miotto, T. (2013). Characterization of the prostate cancer susceptibility gene KLF6 in human and mouse prostate cancers. Prostate, 73(2), 182-193.
DOI Scopus15 WoS13 Europe PMC12
2012 Betterman, K., Paquet- Fifield, S., Asselin-Labat, M., Visvader, J., Butler, L., Stacker, S., . . . Harvey, N. (2012). Remodeling of the lymphatic vasculature during mouse mammary gland morphogenesis is mediated via epithelial-derived lymphangiogenic stimuli. American Journal of Pathology, 181(6), 2225-2238.
DOI Scopus17 WoS16 Europe PMC15
2012 Trotta, A., Need, E., Butler, L., Selth, L., O'Loughlin, M., Coetzee, G., . . . Buchanan, G. (2012). Subdomain structure of the co-chaperone SGTA and activity of its androgen receptor client. Journal of Molecular Endocrinology, 49(2), 57-68.
DOI Scopus19 WoS17 Europe PMC17
2012 Moore, N., Buchanan, G., Harris, J., Selth, L., Bianco-Miotto, T., Hanson, A., . . . Tilley, W. (2012). An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity. Endocrine-Related Cancer, 19(4), 599-613.
DOI Scopus48 WoS47 Europe PMC42
2012 Selth, L., Tilley, W., & Butler, L. (2012). Circulating microRNAs: macro-utility as markers of prostate cancer?. Endocrine-Related Cancer, 19(4), 99-113.
DOI Scopus39 WoS34 Europe PMC33
2012 Dean, J., McClendon, A., Hickey, T., Butler, L., Tilley, W., Witkiewicz, A., & Knudsen, E. (2012). Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle, 11(14), 2756-2761.
DOI Scopus200 WoS186 Europe PMC180
2012 Centenera, M., Gillis, J., Hanson, A., Jindal, S., Taylor, R., Risbridger, G., . . . Butler, L. (2012). Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Clinical Cancer Research, 18(13), 3562-3570.
DOI Scopus96 WoS94 Europe PMC91
2012 Moore, N., Hickey, T., Butler, L., & Tilley, W. (2012). Multiple nuclear receptor signaling pathways mediate the actions of synthetic progestins in target cells. Molecular and Cellular Endocrinology, 357(1-2), 60-70.
DOI Scopus40 WoS40 Europe PMC29
2012 Thompson, V., Day, T., Bianco-Miotto, T., Selth, L., Han, G., Thomas, M., . . . Tilley, W. (2012). A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease. International Journal of Cancer, 131(3), 662-672.
DOI Scopus33 WoS31 Europe PMC30
2012 Selth, L., Townley, S., Gillis, J., Ochnik, A., Murti, K., Macfarlane, R., . . . Butler, L. (2012). Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. International Journal of Cancer, 131(3), 652-661.
DOI Scopus164 WoS152 Europe PMC137
2012 Schiewer, M., Goodwin, J., Han, S., Brenner, J., Augello, M., Dean, J., . . . Knudsen, K. (2012). Dual roles of PARP-1 promote cancer growth and progression. Cancer Discovery, 2(12), 1134-1149.
DOI Scopus379 WoS373 Europe PMC345
2011 Chiam, K., Centenera, M., Butler, L., Tilley, W., & Bianco-Miotto, T. (2011). GSTP1 DNA methylation and expression status is indicative of 5-aza-2'-deoxycytidine efficacy in human prostate cancer cells. PLoS One, 6(9), e25634-1-e25634-11.
DOI Scopus47 WoS39 Europe PMC35
2011 Peters, A., Ingman, W., Tilley, W., & Butler, L. (2011). Differential effects of exogenous androgen and an androgen receptor antagonist in the peri- and postpubertal murine mammary gland. Endocrinology, 152(10), 3728-3737.
DOI Scopus58 WoS49 Europe PMC46
2011 Buchanan, G., Need, E., Barrett, J., Bianco-Miotto, T., Thompson, V., Butler, L., . . . Coetzee, G. (2011). Corepressor effect on androgen receptor activity varies with the length of the CAG encoded polyglutamine repeat and is dependent on receptor/corepressor ratio in prostate cancer cells. Molecular and Cellular Endocrinology, 342(1-2), 20-31.
DOI Scopus13 WoS14 Europe PMC14
2010 Bianco-Miotto, T., Chiam, K., Buchanan, G., Jindal, S., Day, T., Thomas, M., . . . Ricciardelli, C. (2010). Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development. Cancer Epidemiology Biomarkers & Prevention, 19(10), 2611-2622.
DOI Scopus142 WoS119 Europe PMC108
2010 Ochnik, A. M., Jankovic-Karasoulos, T., Cops, E. J., Birrell, S. N., Butler, L. M., Jindall, S., . . . Hickey, T. E. (2010). Medroxyprogesterone acetate impedes 5 alpha-dihydrotesterone induced androgen receptor signaling in normal and malignant human breast epithelial cells. Cancer Research, 70(Suppl 8), 4 pages.
DOI
2010 Murti, K., Butler, L. M., Sakko, A., Ricciardelli, C., Mitto, T. B., Octnick, A., . . . Tilley, W. D. (2010). Androgen receptor levels during progression of prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Medical Journal of Indonesia, 19(1), 5-13.
DOI Scopus2 WoS2
2009 Marrocco, D., Centenera, M., Scher, H., Tilley, W., & Butler, L. (2009). Finding the place of histone deacetylase inhibitors in prostate cancer therapy. Expert Review of Clinical Pharmacology, 2(6), 619-630.
DOI Scopus5 Europe PMC4
2009 Peters, A., Buchanan, G., Ricciardelli, C., Bianco-Miotto, T., Centenera, M., Harris, J., . . . Tilley, W. (2009). Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Research, 69(15), 6131-6140.
DOI Scopus345 WoS322 Europe PMC271
2009 Chiam, K., Tilley, W., Butler, L., & Bianco-Miotto, T. (2009). The dynamic and static modification of the epigenome by hormones: A role in the developmental origin of hormone related cancers. Biochimica et Biophysica Acta-Reviews on Cancer, 1795(2), 104-109.
DOI Scopus16 WoS17 Europe PMC13
2008 Centenera, M., Harris, J., Tilley, W., & Butler, L. (2008). The Contribution of Different Androgen Receptor Domains to Receptor Dimerization and Signaling. Molecular Endocrinology, 22(11), 2373-2382.
DOI Scopus125 WoS113 Europe PMC96
2008 Cops, E., Bianco-Miotto, T., Moore, N., Clarke, C., Birrell, S., Butler, L., & Tilley, W. (2008). Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors. Journal of Steroid Biochemistry and Molecular Biology, 110(3-5), 236-243.
DOI Scopus67 WoS64 Europe PMC53
2007 Buchanan, G., Ricciardelli, C., Harris, J., Prescott, J., Yu, Z., Jia, L., . . . Tilley, W. (2007). Control of androgen receptor signaling in prostate cancer by the cochaperone small glutamine-rich tetratricopeptide repeat containing protein α. Cancer Research, 67(20), 10087-10096.
DOI Scopus79 WoS76 Europe PMC72
2007 Birrell, S., Butler, L., Harris, J., Buchanan, G., & Tilley, W. (2007). Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer. FASEB Journal, 21(10), 2285-2293.
DOI Scopus82 WoS71 Europe PMC64
2007 Robzyk, K., Oen, H., Buchanan, G., Butler, L., Tilley, W., Mandal, A., . . . Caplan, A. (2007). Uncoupling of hormone-dependence from chaperone-dependence in the L701H mutation of the androgen receptor. Molecular and Cellular Endocrinology, 268(1-2), 67-74.
DOI Scopus9 WoS11 Europe PMC9
2007 Marrocco, D., Tilley, W., Bianco-Miotto, T., Evdokiou, A., Scher, H., Rifkind, R., . . . Butler, L. (2007). Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Molecular Cancer Therapeutics, 6(1), 51-60.
DOI Scopus96 WoS86 Europe PMC80
2006 Butler, L., Liapis, V., Bouralexis, S., Welldon, K., Hay, S., Thai, L., . . . Evdokiou, A. (2006). The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. International Journal of Cancer, 119(4), 944-954.
DOI Scopus71 WoS65 Europe PMC53
2006 Butler, L., Centenera, M., Neufing, P., Buchanan, G., Choong, C., Ricciardelli, C., . . . Tilley, W. (2006). Suppression of androgen receptor signaling in prostate cancer cells by an inhibitory receptor variant. Molecular Endocrinology, 20(5), 1009-1024.
DOI Scopus15 WoS14 Europe PMC14
2005 Buchanan, G., Birrell, S., Peters, A., Bianco-Miotto, T., Ramsay, K., Cops, E., . . . Tilley, W. (2005). Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate. Cancer Research, 65(18), 8487-8496.
DOI Scopus63 WoS60 Europe PMC55
2005 Shen, H., Buchanan, G., Butler, L., Prescott, J., Henderson, M., Tilley, W., & Coetzee, G. (2005). GRIP1 mediates the interaction between the amino- and carboxyl-termini of the androgen receptor.. Journal of Biological Chemistry, 386(1), 69-74.
DOI Scopus25 WoS25 Europe PMC21
2005 Wold, R. S., Lopez, S. T., Yau, C. L., Butler, L. M., Pareo-Tubbeh, S. L., Waters, D. L., . . . Baumgartner, R. N. (2005). Increasing trends in elderly persons' use of nonvitamin, nonmineral dietary supplements and concurrent use of medications. Journal of the American Dietetic Association, 105(1), 54-63.
DOI Scopus90
2004 Wayne, S. J., Lopez, S. T., Butler, L. M., Baumgartner, K. B., Baumgartner, R. N., & Ballard-Barbash, R. (2004). Changes in dietary intake after diagnosis of breast cancer. Journal of the American Dietetic Association, 104(10), 1561-1568.
DOI Scopus82 Europe PMC68
2004 Scher, H., Buchanan, G., Gerald, W., Butler, L., & Tilley, W. (2004). Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocrine-Related Cancer, 11(3), 459-476.
DOI Scopus211 WoS205 Europe PMC178
2003 Kutko, M., Glick, R., Butler, L., Coffey, D., Rifkind, R., Marks, P., . . . LaQuaglia, M. (2003). Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro. Clinical Cancer Research, 9(15), 5749-5755.
Scopus61 WoS58 Europe PMC46
2002 Butler, L., Zhou, X., Marks, P., Rifkind, R., & Richon, V. (2002). The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proceedings of the National Academy of Sciences of the United States of America, 99(18), 11700-11705.
DOI Scopus482 WoS465 Europe PMC394
2001 Butler, L., Webb, Y., Agus, D., Higgins, B., Tolentino, T., Kutko, M., . . . Marks, P. (2001). Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clinical Cancer Research, 7(4), 962-970.
Scopus133 WoS124 Europe PMC74
2001 Babidge, W., Butler, L., Burton, M., & Cowled, P. (2001). Methylation of CpG sites in exon 2 of the Bcl-2 gene occurs in colorectal carcinoma. Anticancer Research, 21(4A), 2809-2814.
Scopus16 WoS13 Europe PMC12
2001 Coffey, D., Kutko, M., Glick, R., Butler, L., Heller, G., Rifkind, R., . . . LaQuaglia, M. (2001). The histone deacetylase inhibitor CBHA inhibits growth of human neuroblastoma xenografts in vivo alone and synergistically with all-trans retinoic acid. Cancer Research, 61(9), 3591-3594.
Scopus161 WoS149 Europe PMC98
2000 Butler, L., Dobrovic, A., Bianco-Miotto, T., & Cowled, P. (2000). Promoter region methylation does not account for the frequent loss of expression of the Fas gene in colorectal carcinoma. British Journal of Cancer, 82(1), 131-135.
DOI Scopus21 WoS18 Europe PMC23
2000 Butler, L. M., Agus, D. B., Scher, H. I., Higgins, B., Rose, A., Cordon-Cardo, C., . . . Richon, V. M. (2000). Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Research, 60(18), 5165-5170.
Scopus606 WoS575 Europe PMC427
2000 Coffey, D. C., Kutko, M. C., Glick, R. D., Swendeman, S. L., Butler, L., Rifkind, R., . . . LaQuaglia, M. P. (2000). Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. Medical and Pediatric Oncology, 35(6), 577-581.
DOI Scopus62 WoS60 Europe PMC42
1999 Butler, L., Hewett, P., Fitridge, R., & Cowled, P. (1999). Deregulation of apoptosis in colorectal carcinoma: theoretical and therapeutic implications. Australian and New Zealand Journal of Surgery, 69(2), 88-94.
DOI Scopus43 WoS41 Europe PMC29
1999 Leonardos, L., Butler, L., Hewett, P., Zalewski, P., & Cowled, P. (1999). The activity of caspase-3-like proteases is elevated during the development of colorectal carcinoma.. Cancer Letters, 143(1), 29-35.
DOI Scopus20 WoS16 Europe PMC15
1998 Butler, L., Hewett, P., Butler, W., & Cowled, P. (1998). Down-regulation of Fas gene expression in colon cancer is not a result of allelic loss or gene rearrangement. British Journal of Cancer, 77(9), 1454-1459.
DOI Scopus43 WoS40 Europe PMC34
1997 Harkin, L., Butler, L., & Burcham, P. (1997). Role of G-T transversions in the mutagenicity of alkylperoxyl radicals: induction of alkali-labile sites in bacteriophage M13 mp19.. Chemical Research in Toxicology, 10(5), 575-581.
DOI Scopus17 WoS17 Europe PMC6

Year Citation
2025 Scheinberg, T., Kench, J. G., Ferguson, P., Sutherland, S., Stockler, M. R., Mahon, K. L., . . . Horvath, L. (2025). LEEP: A randomised, window of opportunity, neoadjuvant trial examining the pharmacodynamic effects of ribociclib prior to radical prostatectomy for high-risk, localised prostate cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 43 (pp. 1 page). LIPPINCOTT WILLIAMS & WILKINS.
DOI
2025 Rodrigues, S. D., Teixeira, I. F., Fanelli, G. N., Ribeiro, C. F., Socciarelli, F., Jiang, J., . . . Loda, M. (2025). Disrupting lipid elongation impairs prostate cancer progression in c-MYC driven mouse models. In CANCER RESEARCH Vol. 85 (pp. 3 pages). IL, Chicago: AMER ASSOC CANCER RESEARCH.
DOI
2023 Mah, C. Y., Nguyen, A. D., Niijima, T., Helm, M., Dehairs, J., Ryan, F. J., . . . Butler, L. M. (2023). Uncovering a novel role of peroxisomal β-oxidation in advanced, treatment-resistant prostate cancer. In CANCER RESEARCH Vol. 83 (pp. 2 pages). FL, Orlando: AMER ASSOC CANCER RESEARCH.
DOI
2023 Scott, J. S., Young, R., Irani, S., Dehairs, J., Blanksby, S., Swinnen, J. V., . . . Butler, L. M. (2023). A fat lot of good: A novel monounsaturated fatty acid promotes prostate cancer growth and survival. In CANCER RESEARCH Vol. 83 (pp. 2 pages). CO, Denver: AMER ASSOC CANCER RESEARCH.
DOI
2022 Mak, B., Lin, H. -M., Mahon, K. L., Joshua, A. M., Stockler, M. R., Gurney, H., . . . Horvath, L. (2022). Modulation of the plasma lipidomic profile with simvastatin in metastatic castration-resistant prostate cancer (mCRPC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 40 (pp. 3 pages). ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS.
DOI WoS1
2017 Nassar, Z. D., Centenera, M. M., Machiels, J., Polacek, S. J., Bloch, K., Tilley, W. D., . . . Butler, L. (2017). Lipid elongation: an unexplored therapeutic target in prostate cancer. In CANCER RESEARCH Vol. 77 (pp. 2 pages). Washington, DC: AMER ASSOC CANCER RESEARCH.
DOI
2017 Shafi, A. A., Schiewer, M. J., de Leeuw, R., McCue, P. A., Gomella, L. G., Lallas, C. D., . . . Knudsen, K. E. (2017). PDeX (Patient Derived eXplant) models to determine the basis for response to targeted agents in prostate cancer. In CANCER RESEARCH Vol. 77 (pp. 2 pages). Washington, DC: AMER ASSOC CANCER RESEARCH.
DOI
2017 Tran, L. N. K., Kichenadasse, G., Ormsby, R. J., Morel, K. L., Butler, L. M., Centenera, M. M., & Sykes, P. J. (2017). COMBINATION OF METFORMIN AND SODIUM VALPROATE FOR PROSTATE CANCER: A RAPID APPROACH FROM BENCH TO CLINICAL TRIAL.. In JOURNAL OF UROLOGY Vol. 197 (pp. E1108-E1109). Boston, MA: ELSEVIER SCIENCE INC.
DOI
2016 Tran, L. N. K., Kichenadasse, G., Morel, K. L., Ormsby, R. J., Butler, L. M., Centenera, M. M., & Sykes, P. J. (2016). Combination of metformin and valproic acid in personalized prostate cancer treatment: the role of p53 and androgen receptor signaling. In CANCER RESEARCH Vol. 76 (pp. 4 pages). New Orleans, LA: AMER ASSOC CANCER RESEARCH.
2016 Oesterreich, S., Katz, T., Logan, G., Levine, K., Nagle, A., Huo, Z., . . . Butler, L. (2016). Potential role of prolactin signaling in development and growth of the lobular subtype of breast cancer. In CANCER RESEARCH Vol. 76 (pp. 1 page). San Antonio, TX: AMER ASSOC CANCER RESEARCH.
DOI
2016 Jankowitz, R., McAuliffe, P., Sikora, M., Butler, L., Ahrendt, G., Johnson, R., . . . Oesterreich, S. (2016). A neoadjuvant window trial of endocrine response in women with invasive lobular carcinoma. In CANCER RESEARCH Vol. 76 (pp. 2 pages). San Antonio, TX: AMER ASSOC CANCER RESEARCH.
DOI
2015 Johnson, I. R. D., Parkinson-Lawrence, E. J., Butler, L. M., O'Leary, J. J., & Brooks, D. A. (2015). Altered Endosome Biogenesis in Prostate Cancer Has Prognostic Potential. In JOURNAL OF PATHOLOGY Vol. 237 (pp. S17). Univ Coll D, Dublin, IRELAND: WILEY-BLACKWELL.
2012 Ochnik, A. M., Moore, N. L., Birrell, S. N., Butler, L. M., Jindal, S., Selth, L., . . . Hickey, T. E. (2012). The combined actions of DHT and MPA lead to altered AR signaling in normal and malignant post-menopausal breast epithelial cells. In Cancer Research Vol. 72 (pp. 2). Chicago, IL: American Association for Cancer Research.
DOI
2009 Lee, M., Labrinidis, A., Liapis, V., Hay, S., Zinonos, I., Butler, L., . . . Evdokiou, A. (2009). The histone deacetylase inhibitor, LBH589 blocks osteoclastogenesis, enhances osteoblast activity and reduces tumor burden in bone. In CANCER RESEARCH Vol. 69 (pp. 1 page). AMER ASSOC CANCER RESEARCH.
2009 Butler, L., Centenera, M., Marrocco, D., Carter, S., Bianco-Miotto, T., & Tilley, W. (2009). A novel combinatorial approach using androgen receptor-targeted agents for treatment of prostate cancer. In Cancer Research Vol. 69 (pp. 2 pages). American Association for Cancer Research.
2006 Murphy, N., Bianco-Miotto, T., Ricciardelli, C., Ruiz, A., Segara, D., McNeil, C., . . . Tilley, W. (2006). Expression of the androgen receptor and its association with disease outcome in breast cancer. In Breast Cancer Research and Treatment Vol. 100 (pp. S262-S263). San Antonio, Texas: Springer.
2005 Evdokiou, A., Minh, L. T., Labrinidis, A., Hay, S., Liapis, V., Bouralexis, S., . . . Findlay, D. M. (2005). Apo2L/TRAIL is a potent anticancer agent that prevents breast cancer-induced bone destruction in a mouse model. In JOURNAL OF BONE AND MINERAL RESEARCH Vol. 20 (pp. P35). Bethesda, MD: AMER SOC BONE & MINERAL RES.

Year Citation
2025 Scheinberg, T., Bonnitcha, P., Butler, L., Davis, I. D., Harri, C., Joshua, A. M., . . . Horvath, L. G. (2025). DARO-LIPID (ANZUP2205): A randomised phase 2 study of sphingosine kinase inhibitor (opaganib) with darolutamide in poor prognostic metastatic castration resistant prostate cancer (mCRPC) based on a circulating lipid biomarker, PCPro. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
2023 Horvath, L., Lin, H. -M., Huynh, K., Meikle, T., Joshua, A. M., Azad, A., . . . Meikle, P. (2023). Circulating ether lipids in prostate cancer. Poster session presented at the meeting of Abstracts of the American Society of Clinical Oncology Annual Meeting I (ASCO 2023), as published in Journal of Clinical Oncology. Chicago, IL: Lippincott Williams & Wilkins.
DOI
2023 Cilento, M. A., Mah, C. Y., Martelotto, L., Sweeney, C. J., & Butler, L. M. (2023). Multiomic analysis workflow for biomarker discovery in human prostate cancer. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
2022 Strach, M. C., Yeung, N., Lin, H. -M., Ansari, N., Koh, C., Shin, J. -S., . . . Mahon, K. (2022). Patient-derived explant model of appendiceal cancer.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS.
2021 Lin, H. -M., Mak, B., Huynh, K., Kwan, E. M., Fettke, H., Tran, B., . . . Horvath, L. G. (2021). Association of ceramide metabolism with resistance to androgen receptor signalling inhibitors in metastatic prostate cancer. Poster session presented at the meeting of Abstracts of the European Society for Medical Oncology Congress (ESMO 2021), as published in Annals of Oncology. online: Elsevier.
DOI
2020 Lin, H. -M., Huynh, K., Kohli, M., Tan, W., Azad, A., Yeung, N., . . . Horvath, L. (2020). Lipidomic analysis of circulating lipids across the natural history of prostate cancer identifies aberrant ceramide metabolism. Poster session presented at the meeting of Abstracts of the Mini Annual Scientific Meeting ANZUP 2020, as published in Asia-Pacific Journal of Clinical Oncology. Adelaide, SA: Wiley.
2020 Gieniec, K., Kobayashi, H., Lannagan, T., Wang, T., Asai, N., Mizutani, Y., . . . Worthley, D. (2020). Melanoma cell adhesion molecule defines a proliferative subset of leptin receptor-lineage cells that substantially contribute to the colorectal cancer stroma. Poster session presented at the meeting of JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY. WILEY.
2020 Kobayashi, H., Gieniec, K., Wright, J., Wang, T., Asai, N., Mizutani, Y., . . . Woods, S. (2020). Stromal imbalance of bone morphogenetic protein signaling drives colorectal carcinogenesis. Poster session presented at the meeting of JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY. WILEY.
2020 Shrestha, R. K., Townley, S., Hanson, A., Pickering, M., Nassar, Z. D., Mah, C. Y., . . . Selth, L. A. (2020). ACSM1 and ACSM3 regulate fatty acid oxidation in prostate cancer to promote growth and protect against oxidative stress.. Poster session presented at the meeting of CANCER RESEARCH. ELECTR NETWORK: AMER ASSOC CANCER RESEARCH.
WoS3
2020 Horvath, L. G., Lin, H. -M., Mak, B., Mahon, K., Yeung, N., Docanto, M., . . . Butler, L. (2020). Lipidomic analysis of circulating lipids across the natural history of prostate cancer identifies aberrant ceramide metabolism. Poster session presented at the meeting of CANCER RESEARCH. ELECTR NETWORK: AMER ASSOC CANCER RESEARCH.
DOI
2020 Butler, L. M., Mah, C. Y., Dehairs, J., Vincent, A., Mutuku, S., Spotbeen, X., . . . Swinnen, J. (2020). Phospholipid profiling of clinical prostate tissues reveals targetable alterations in membrane lipid composition accompanying tumorigenesis. Poster session presented at the meeting of CANCER RESEARCH. ELECTR NETWORK: AMER ASSOC CANCER RESEARCH.
DOI WoS1
2020 Mah, C. Y., Nassar, Z. D., Burvenich, I. J., Irani, S., Centenera, M. M., Moldovan, M., . . . Butler, L. M. (2020). DECR1: The rate limiting enzyme of polyunsaturated fatty acid metabolism and a novel therapeutic target in prostate cancer. Poster session presented at the meeting of CANCER RESEARCH. ELECTR NETWORK: AMER ASSOC CANCER RESEARCH.
DOI
2019 Shafi, A. A., Schiewer, M. J., de Leeuw, R., Dylgjeri, E., Mccue, P. A., Shah, N., . . . Knudsen, K. E. (2019). Patient derived models reveal impact of the tumor microenvironment on therapeutic response. Poster session presented at the meeting of CANCER RESEARCH. Atlanta, GA: AMER ASSOC CANCER RESEARCH.
DOI
2019 Scheinberg, T., Kench, J., Stockler, M., Mahon, K. L., Sebastian, L., Stricker, P., . . . Horvath, L. G. (2019). Pharmacodynamics Effects of CDK4/6 Inhibitor LEE011 (Ribociclib) in High-Risk, Localised Prostate Cancer: A Study Protocol for a Randomised Controlled Phase II Trial (Leep Study). Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
2019 Butler, L., Irani, S., Centenera, M., Ryan, N., Pegg, N., & Brooks, A. N. (2019). Preclinical investigation of a small molecule inhibitor of p300/CBP reveals efficacy in patient-derived prostate tumor explants.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
DOI WoS2
2018 Mutuku, S. M., Centenera, M. M., Trim, P. J., Snel, M. F., & Butler, L. M. (2018). Evaluation of small molecule drug uptake in <i>ex vivo</i> cultured clinical prostate tumours by mass spectrometry. Poster session presented at the meeting of BJU INTERNATIONAL. Brisbane, AUSTRALIA: WILEY.
2018 Zhang, A., Chiam, K., Haupt, Y., Fox, S., Birch, S., Tilley, W., . . . Kench, J. (2018). An analysis of multiple biomarkers to better predict prostate cancer metastasis after radical prostatectomy. Poster session presented at the meeting of Asia-Pacific Journal of Clinical Oncology. Adelaide: Wiley.
2018 Nassar, Z. D., Centenera, M. M., Machiels, J., Zinonos, I., Hanson, A., Bloch, K., . . . Swinnen, J. V. (2018). Lipid elongation in prostate cancer is androgen regulated and a potential therapeutic target. Poster session presented at the meeting of BJU International. Brisbane, Australia: Wiley.
2018 Butler, L. M. (2018). New Insights into Prostate Tumour Heterogeneity from Studying the "Lipidome". Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
2018 Zhang, A., Chiam, K., Haupt, Y., Fox, S., Birch, S., Tilley, W., . . . Kench, J. (2018). An analysis of multiple biomarkers to better predict prostate cancer metastasis after radical prostatectomy. Poster session presented at the meeting of Asia-Pacific Journal of Clinical Oncology. Sydney: Wiley.
2018 Zhang, A. Y., Chiam, K., Haupt, Y., Fox, S. B., Birch, S., Tilley, W., . . . Kench, J. (2018). An analysis of multiple biomarkers to better predict prostate cancer metastasis and death after radical prostatectomy. Poster session presented at the meeting of Journal of Clinical Oncology. San Francisco, CA: American Society of Clinical Oncology.
DOI
2017 Mutuku, S. M., Centenera, M., Trim, P., Gustafsson, O. J., Snel, M., & Butler, L. (2017). A Mass Spectrometry Approach to Characterise Lipid Composition in Prostate Tumuors. Poster session presented at the meeting of 11th Florey Postgraduate Research Conference. Adelaide.
2017 Aref, A. T., Vincent, A., O'Callaghan, M., Hoy, A., Butler, L., & Wittert, G. (2017). The inverse relationship between prostate specific antigen (PSA) and obesity in healthy men; support for a hormonal, rather than haemodilution mechanism. Poster session presented at the meeting of Abstracts of the 2017 ANZUP Annual Scientific Meeting, as published in Asia-Pacific Journal Of Clinical Oncology. Melbourne, VIC: Wiley.
DOI
2017 Mutuku, S. M., Prabhala Bala., Centenera, M., Trim, P., Snel, M., & Butler, L. (2017). Quantification of Enzalutamide in Cultured Prostate Tissue Using LC-MS/MS. Poster session presented at the meeting of 26th Australian and New Zealand Society for Mass Spectrometry. Flinders University.
2017 Butler, L. (2017). IDENTIFICATION OF DRUG RESPONSE BIOMARKERS IN PATIENT-DERIVED PROSTATE EXPLANTS. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
2016 Nassar, Z. D., Centenera, M. M., Machiels, J., Polacek, S. J., Bloch, K., Tilley, W. D., . . . Swinnen, J. V. (2016). Androgenic regulation of lipid elongation in prostate cancer. Poster session presented at the meeting of BJU International. Melbourne: Wiley.
2015 Johnson, I. R. D., Parkinson-Lawrence, E. J., Brooks, D. A., Butler, L., & O'Leary, J. J. (2015). Altered Endosome Biogenesis in Prostate Cancer Identifies Potential Diagnostic Biomarkers. Poster session presented at the meeting of JOURNAL OF PATHOLOGY. Univ Coll D, Dublin, IRELAND: WILEY-BLACKWELL.
2015 Armstrong, H., Butler, L., Selth, L., Tarulli, G., & Centenera, M. (2015). The Hsp90 inhibitor, NVP-AUY922, produces anti-tumour activity through inhibition of fibronectin polymerization resulting in cytoskeletal reorganization. Poster session presented at the meeting of BJU INTERNATIONAL. Cairns, AUSTRALIA: WILEY-BLACKWELL.
2014 Roberts, M., Selth, L., Chow, C., Doi, S., Vincent, A., Butler, L., . . . Gardiner, R. (2014). Seminal fluid microRNAs: new, non-invasive biomarkers for prostate cancer. Poster session presented at the meeting of BJU International. Brisbane: Wiley.
2014 Zhang, A. Y., Butler, L. M., Stricker, P. D., Kench, J. G., Tilley, W. D., Sebastian, L., . . . Horvath, L. (2014). Pharmacodynamic effects of the heat shock protein 90 (HSP90) inhibitor, AUY922, in high-risk, localised prostate cancer. Poster session presented at the meeting of Asia-Pacific Journal Of Clinical Oncology. Melbourne, Vic.: Wiley.
DOI WoS1
2014 Philp, L. K., Day, T. K., Butler, M. S., Jindal, S., Butler, L. M., & Tilley, W. D. (2014). Full, but Not Partial, Sgta Ablation Confers Subfertility and Limits Offspring Viability and Growth in Mice. Poster session presented at the meeting of ENDOCRINE REVIEWS. ENDOCRINE SOC.
2014 Zhuang., Rodriguez Lopez., Chiam, K., Harryanto, H., Ryan, N., Jindal, S., . . . Bianco-Miotto. (2014). A high fat diet early in life and prostate cancer risk. Poster session presented at the meeting of The Australian Health and Medical Research Congress. Melbourne, Australia.
2013 Philp, L., Day, T., Jindal, S., Pickering, M., Butler, L., & Tilley, W. (2013). Protein expression alterations in a unique gleason prostate cancer progression cohort. Poster session presented at the meeting of BJU International. Melbourne: Wiley.
2013 Selth, L., Townley, S., Bert, A., Stricker, P., Sutherland, P., Horvath, L., . . . Tilley, W. (2013). CIRCULATING microRNAs PREDICT BIOCHEMICAL RECURRENCE IN PROSTATE CANCER PATIENTS. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY-BLACKWELL.
2012 Butler, L. M. (2012). DEVELOPMENTAL THERAPEUTICS. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY-BLACKWELL.
2010 Centenera, M. M., Treloar, J. L., Hanson, A., Sutherland, P., Tilley, W. D., & Butler, L. M. (2010). Evaluation of the synthetic heat shock protein 90 inhibitors NVP-AUY922 and NVP-HSP990 in human prostate cancer tissue. Poster session presented at the meeting of European Journal of Cancer Supplements. Berlin, Germany: Elsevier.
DOI
2008 Hickey, T., Ocknik, A., Bianco-Miotto, T., Birrell, S., Butler, L., & Tilley, W. (2008). Functional androgen signaling in an explant model of normal human breast tissue. Poster session presented at the meeting of Biology of Reproduction. Kailua-Kona, Hawaii: Oxford University Press.
DOI
2006 Buchanan, G., Ricciardelli, C., Prescott, J., Harris, J. M., Yu, Z. C. -L., Jia, L., . . . Tilley, W. D. (2006). αSGT: A critical determinant of androgen receptor function in prostate cancer. Poster session presented at the meeting of Cancer Research. Washington, DC: American Association for Cancer Research.

Year Citation
2020 Brooks, D., Parkinson-Lawrence, E., Johnson, I., & Butler, L. (2020). 15/794,270, Methods for detecting prostate cancer by determining the ratio of early to late endosomal markers. United States.
2020 Brooks, D., O'Leary, J., Logan, J., Sorvina, A., Martino, C., Johnson, I., . . . Butler, L. (2020). PCT/AU2020/050925, Methods for Confirming Detection and Evaluating the Progression of a Prostate Cancer - II. Australia.
2016 Brooks, D., Parkinson Lawrence, E., Johnson, I., Butler, L., & Weigert, R. (2016). EP3008210, Methods for detecting prostate cancer.
2003 Richon, V., Marks, P., Rifkind, R., & Butler, L. (2003). WO/2003/070188, Method of treating TRX mediated inflammatory diseases. United States Patent US2003235588.

Year Citation
2024 Heatlie, J., Lazniewska, J., Moore, C., Johnson, I. R. D., Nturubika, B., Williams, R., . . . Brooks, D. (2024). Prostate Cancer Intercellular Communication.
DOI
2023 Wang, T., Harvey, K., Morlanes, J. E., Kiedik, B., Al-Eryani, G., Greenwald, A., . . . Martelotto, L. (2023). snPATHO-seq: unlocking the pathology archives.
DOI Europe PMC3
2023 Jiménez-Gracia, L., Marchese, D., Nieto, J., Caratù, G., Melón-Ardanaz, E., Gudiño, V., . . . Martelotto, L. (2023). FixNCut: Single-cell genomics through reversible tissue fixation and dissociation.
DOI Europe PMC1
2023 Cook, D., Jensen, K., Wise, K., Roach, M., Dezem, F. S., Ryan, N., . . . Martelotto, L. (2023). A Comparative Analysis of Imaging-Based Spatial Transcriptomics Platforms.
DOI Europe PMC12

 

FELLOWSHIPS

  • Cancer Council of SA Beat Cancer Principal Research Fellowship. BUTLER LM. From bedside to bench to bedside: improving prognosis and treatment of prostate cancer. 2018-2022. $600,000.
  • Australian Research Council Future Fellowship. BUTLER LM. Molecular hallmarks of androgen receptor targeting in prostate cancer. 2014-2018. $846,240.
  • Cancer Council of SA Senior Research Fellowship. BUTLER LM. Androgen Signalling in the normal human breast: role and implications for breast cancer risk. 2008-2012. $276,000.
  • Royal Adelaide Hospital/IMVS Florey Research Fellowship. BUTLER LM. The role of androgen receptor signalling in the normal human breast. 2006-2008. $237,180.
  • Prostate Cancer Foundation of Australia Postdoctoral Fellowship. BUTLER LM. Dominant negative androgen receptors: a novel strategy for treatment of advanced prostate cancer. 2003-2005. $300,000.

 

GRANT FUNDING

  • Australian Research Council Discovery Project. BUTLER LM, Selth LA, Hoy AJ, Lynn DJ, Swinnen JV. Androgen receptor: a master regulator of lipid metabolism. 2023-2026. $614,000.
  • Cancer Council NSW. BUTLER LM, Centenera MM. A patient-derived platform for drug development in prostate cancer. 2022-2025. $433,228.
  • US Department of Defense. Labbe D, Corey E, Mucci L, Horvath L, Butler LM. Precision nutrition increases efficacy of DNA-damaging therapies in prostate cancer. 2022-2027. $USD 2,000,000.
  • Cancer Australia. Selth LA, Wang S, BUTLER LM, Taylor RA, Holst J. Targeting CDK9 in lethal prostate cancer. 2022-2025. $459,000.
  • Cancer Council of SA Women in Leadership Award. BUTLER LM. 2021. $59,976.
  • The Hospital Research Foundation Prostate Cancer Project Grant. Centenera MM, BUTLER LM, Horvath LG. A patient-derived discovery platform for companion biomarker development in prostate cancer. 2021-2022. $149,662.
  • The Hospital Research Foundation Prostate Cancer Project Grant. Nassar ZD, Xie J, BUTLER LM, Selth LA. Targeting Fatty Acid Oxidation for Treatment of High Risk Localised Prostate Cancer. 2021-2022. $149,956.
  • Medical Research Future Fund Biomedical Translation Bridge (MTP Connect) / Envision Sciences Pty. Ltd./University of South Australia.  Brooks DA, O’Leary JJ, Pursey P, Morretti K, Klebe S, Samaratunga H, Delahunt B, Karageorgos L, Esterman A, Dinan A, Brooks RD, Logan J, Sorvina A, Martino C, BUTLER  L, Ung B Diagnosis and prognosis of prostate cancer using blood and tissue tests. 2020-21. $2,400,000.
  • Tour de Cure Project Grant. Holst J, BUTLER LM. A new therapy targeting “gluttonous” prostate cancer cells. 2020-2021. $200,000.
  • US Department of Defense Prostate Cancer Research Program Idea Development Award. Loda M, BUTLER LM, Swinnen JV. Lipid elongation via ELOVL5: a novel target for advanced prostate cancer. 2019-2022. $USD 736,817.
  • UniSA Division of Health Sciences and UniSA Innovation Services. Brooks DA, Logan J, Martino C, Sorvina A, Johnson I, BUTLER L, Selemidis S, O’Leary J, Pursey P. UniSA Support Grant for Cancer Research Translation Programme. 2019-2022. $1,632,000.
  • Cancer Australia Project Grant. BUTLER LM, Lynn DJ, Hayes VM, Horvath LG, Mills IG and Centenera MM. Novel co-extinction strategies for treatment of prostate cancer. 2017-2021. $596,409.
  • Cancer Australia Project Grant. BUTLER LM, Horvath LJ, Tilley WD, Stocker M, Stricker PD and Kench JD. A randomised controlled Phase II trial of the pharmacodynamic effects of the Cdk4/6 inhibitor, LEE011, in high-risk, localised prostate cancer. 2016-2020. $590,408.
  • Movember Foundation / Prostate Cancer Foundation of Australia Revolutionary Team Award. BUTLER LM, Swinnen JV, Tilley WD, Scott AM, Hoy AJ and Wittert GA. Exploiting alterations in lipid metabolism to improve diagnosis, treatment and molecular imaging of prostate cancer. Phase 1: 2015-2018. $3,250,000. Phase 2: 2019-2021. $2,000,000.
  • Prostate Cancer Foundation of Australia Novel Concept Grant. BUTLER LM and Voelcker N. Next-generation prostate cancer therapies based on precision nanomedicines. 2017-2018. $99,919.
  • Cancer Australia Project Grant. BUTLER LM, Daly R, Tilley WD, Horvath LG and Centenera MM. Molecular hallmarks of heat shock protein 90 inhibition in prostate cancer. 2015-2018. $553,483.
  • NHMRC Development Grant. Brooks DA, BUTLER LM and O’Leary JJ. Development of effective biomarkers for the diagnosis and prognosis of Prostate Cancer. 2015-2017. $1,029,873.
  • Cancer Australia Project Grant. Tilley WD, BUTLER LM, Plymate S and Selth LA. Mechanism and targeting of castration resistant prostate cancer. 2013-2015. $586,398.
  • Ray and Shirl Norman Cancer Research Trust Research Grant. Tilley WD, BUTLER LM, Selth LA and Parnis F. Targeting androgen receptor variant signalling in lethal prostate cancer. 2013-2014. $327,184.
  • Royal Adelaide Hospital Clinical Project Grant. Centenera MM and BUTLER LM. Evaluation of biomarkers of response to Hsp90 inhibition in human prostate cancer. 2013. $48,000.
  • Royal Adelaide Hospital Clinical Project Grant. BUTLER LM, Brook N, Sutherland P and Saunders P.  Development of an Australian prostate cancer reference cohort to support research identifying better biomarkers that predict disease progression. 2013. $18,000.
  • Prostate Cancer Foundation of Australia New Directions Development Award. BUTLER LM, Centenera MM, Claessens F and Swinnen JV. Exploiting metabolic alterations to more accurately monitor prostate cancer therapy. 2012-2013. $299,817.
  • Cancer Australia Project Grant. Tilley WD, BUTLER LM, Hoffman P, Goodall G and Scher HI. A novel approach to predict metastatic potential at prostate cancer diagnosis. 2011-2013. $591,732.
  • Prostate Cancer Foundation of Australia Project Grant. Buchanan G, Kee T and BUTLER LM. Targeting chemokine signalling in prostate cancer. 2011-2012. $250,000.
  • RAH/IMVS Research Committee Clinical Project Grant. Centenera MM, BUTLER LM and Tilley WD. Identification of biomarkers of response to Hsp90 inhibition in human prostate cancer. 2011. $20,000.
  • Cancer Australia/Prostate Cancer Foundation of Australia Project Grant. BUTLER LM, Tilley WD and Scher HI. A combinatorial approach targeting androgen signalling for treatment of prostate cancer. 2010-2012. $589,673.
  • NHMRC Project Grant. Tilley WD, BUTLER LM, Scher H and Bianco-Miotto T. The essential role of androgen receptor signalling in prostate tumorigenesis. 2010-2012. $813,913.
  • RAH/IMVS Research Committee Clinical Project Grant. BUTLER LM. A novel explant model for the investigation of hormone signalling and novel treatments in human prostate tissue. 2010. $20,000.
  • NHMRC Project Grant. Evdokiou A, Findlay DM and BUTLER LM. Histone Deacetylase Inhibitors (HDIs) with antineoplastic and antiosteolytic properties. 2008-2010. $513,750.
  • US Army Medical Research and Material Command Congressionally Directed Medical Research Programs.  Tilley WD, BUTLER LM and Marshall VR. Mechanism of Prostate Cancer Tumorigenesis. 2007-2010. $USD 482,622.
  • NHMRC Project Grant. Tilley WD, BUTLER LM and Marshall VR. Androgen receptor signalling in development and progression of prostate cancer. 2007-2009. $723,750.
  • National Breast Cancer Foundation of Australia. Androgen receptor status as a determinant of breast cancer risk. Tilley WD, BUTLER LM, Roder DM and Gelareh F. 2007-2008. $168,000.
  • US Army Medical Research and Material Command Congressionally Directed Medical Research Programs.  Kennaway DJ, Tilley WD and BUTLER LM. Disruption of the circadian rhythms of gene expression and the development of breast cancer. 2006-2008. $USD 381,818.
  • National Breast Cancer Foundation of Australia. Evdokiou A, BUTLER LM and Findlay DM. TRAIL in breast cancer therapy. 2006-2008. $254,004.
  • Cancer Council of South Australia. Tilley WD, BUTLER LM, Roder D and Farshid G. Androgen receptor status as a determinant of breast cancer risk. 2006. $76,000.
  • The Susan G Komen Breast Cancer Foundation. BUTLER LM, Tilley WD and Birrell SN. Role of androgen signalling in the breast: disruption by synthetic progestins. 2005-2008. $USD 333,332.
  • Cancer Council of South Australia. Evdokiou A, BUTLER LM and Findlay DM. Inhibition of breast cancer growth in, and metastasis to, bone using TRAIL therapy. 2005. $64,125.
  • NHMRC Project Grant. Tilley WD, BUTLER LM and Marshall VR. Androgen receptor signalling and progression of prostate cancer. 2004-2006. $455,250,
  • US Army Medical Research and Materiel Command, Breast Cancer Research Program. Kennaway DJ, BUTLER LM and Tilley WD. Clock genes: critical modulators of breast cancer risk? 2004-2005. $USD 99,485.
  • US Army Medical Research and Materiel Command. Tilley WD, BUTLER LM and Birrell SN. The role of androgen receptor signalling in breast cancer. 2003-2006. $USD 350,121.
  • NHMRC Project Grant. Tilley WD, BUTLER LM and Birrell SN. Inhibition of estrogen signalling by the androgen receptor: a potential mechanism of suppression of breast cancer cell growth by androgens. 2003-2005. $375,000.

 

PREVIOUS COMMERCIAL FUNDING

  • Envision Sciences Pty. Ltd. Translational Research Grant. Brooks DA, O’Leary JJ, Brooks RD, Logan J, Sorvina A, Martino C, BUTLER L, Johnson I, Hickey S, Selemidis S, Parkinson-Lawrence EJ, Orgeig S, Lazniewska J, Thomas C, Dale B, Ung B, Bader C, Morrow I, Chappell N, Moore C, Reynolds P, Esterman A, Karageorgos L. Development Program: Biomarkers and therapeutics for prostate and other cancers. 2020. $2,000,000.
  • Envision Sciences Pty. Ltd. Translational Research Grant. Brooks DA, O’Leary JJ, Brooks RD, Logan J, Sorvina A, Martino C, BUTLER L, Johnson I, Hickey S, Selemidis S, Parkinson-Lawrence EJ, Orgeig S, Lazniewska J, Thomas C, Dale B, Ung B, Bader C, Reynolds P, Esterman A, Olver I. Companion diagnostics and therapeutics for cancer. 2019. $2,350,000.
  • AusHealth Project Grant. BUTLER LM, Ranieri E. Lipid screening for prostate cancer prognosis. 2018-2020. $200,000.
  • Envision Sciences Pty. Ltd. Translational Research Grant. Brooks DA, Plush S, Massi M, Brooks RD, O’Leary JJ, BUTLER L, Sorvina A, Bader C. Visualising the pathogenesis in cancer and developing novel therapeutics. 2017-2018. $1,019,225.
  • Envision Sciences Pty. Ltd. Translational Research Grant. Brooks DA, O’Leary JJ, BUTLER L, Johnson I, Selemidis S, Parkinson-Lawrence EJ, Sorvina A, Olver I, Esterman A. Prostate cancer diagnosis and prognosis. 2017-19. $2,930,165.

 

EQUIPMENT FUNDING

  • Australian Cancer Research Foundation. Hughes TP, Zannettino ACW, White DL, Proud CG, Wesselingh SL, Lynn DJ, BUTLER LM, Gronthos S, Tilley WD and Bulone V. ACRF Centre for Integrated Cancer Systems Biology. 2018-2022. $2,500,000.

 

In addition to her extensive supervision of post-graduate students, Prof Butler has several roles in undergraduate teaching at The University of Adelaide.

 

LECTURING

  • Biochemistry III – 3 lectures/year (2016-present)
  • Masters of Biotechnology (Biomedical) – 1 lecture/year (2014-2017)
  • Comparative Reproductive Biology of Mammals III - 1 lecture/year (2011-2017)
  • Structural Cell Biology III – 6 lectures/year (2011-2016)

 

LABORATORY SUPERVISION

  • Laboratory-based research projects as part of Level 3 Physiology and Medical Science, and Level 3 Biochemistry (2003-present)
  • Summer vacation projects and scholarship program (2003-present)

 

STATE-WIDE RESEARCH TRAINING

  • Teaching of annual workshop on Human Ethics for Laboratory Research- provided to all higher degree research students from the University of Adelaide, UniSA and Flinders University of SA (2009-2012)

Date Role Research Topic Program Degree Type Student Load Student Name
2025 Principal Supervisor Integrating multi-omics data to identify novel biomarkers for improved disease diagnosis and prognosis Doctor of Philosophy Doctorate Full Time Miss Anxuan Han
2025 Principal Supervisor Integrating multi-omics data to identify novel biomarkers for improved disease diagnosis and prognosis Doctor of Philosophy Doctorate Full Time Miss Anxuan Han
2024 Principal Supervisor Discovering lipid biomarkers of response to ribociclib in clinical prostate cancer tissues Doctor of Philosophy Doctorate Full Time Miss Suzanne Rajesh
2024 External Supervisor - Doctor of Philosophy Doctorate Full Time Miss Madison Tyler Hindes
2024 Principal Supervisor Discovering lipid biomarkers of response to ribociclib in clinical prostate cancer tissues Doctor of Philosophy Doctorate Full Time Miss Suzanne Rajesh
2023 Co-Supervisor Novel Target Discovery for TP53 Mutated clonal Haematopoiesis Doctor of Philosophy Doctorate Full Time Mr Hossein Anani
2023 Principal Supervisor The impact of high fat diet on plasma ceramides and prostate tumour metastasis Doctor of Philosophy Doctorate Full Time Miss An Dieu Trang Nguyen
2023 Principal Supervisor Identifying novel metabolic drivers of lethal prostate cancer Doctor of Philosophy Doctorate Full Time Dr Michael Cilento
2023 Co-Supervisor Examining the Influence of Fatty Acid Oxidation on Prostate Cancer Progression: An Epigenetic Exploration. Doctor of Philosophy Doctorate Full Time Mr Ez Aldeen Ismael Esawi
2023 Co-Supervisor Synthetic lethality-based identification of metabolic targets for prostate cancer treatment Doctor of Philosophy Doctorate Full Time Mr Mohammad Asaad Ibrahim Ismail
2023 Co-Supervisor How pluripotent transcription factors reshape the prostate cancer epigenetic landscape to reprogram the cell fate toward neuroendocrine-like with their cofactors Doctor of Philosophy Doctorate Full Time Mr Tianjun Zhang
2023 Principal Supervisor Identifying novel metabolic drivers of lethal prostate cancer Doctor of Philosophy Doctorate Full Time Dr Michael Cilento
2023 Co-Supervisor Synthetic lethality-based identification of metabolic targets for prostate cancer treatment Doctor of Philosophy Doctorate Full Time Mr Mohammad Asaad Ibrahim Ismail
2023 Principal Supervisor The impact of high fat diet on plasma ceramides and prostate tumour metastasis Doctor of Philosophy Doctorate Full Time Miss An Dieu Trang Nguyen
2023 Co-Supervisor How pluripotent transcription factors reshape the prostate cancer epigenetic landscape to reprogram the cell fate toward neuroendocrine-like with their cofactors Doctor of Philosophy Doctorate Full Time Mr Tianjun Zhang
2023 Co-Supervisor Novel Target Discovery for TP53 Mutated clonal Haematopoiesis Doctor of Philosophy Doctorate Full Time Mr Hossein Anani
2023 Co-Supervisor Examining the Influence of Fatty Acid Oxidation on Prostate Cancer Progression: An Epigenetic Exploration. Doctor of Philosophy Doctorate Full Time Mr Ez Aldeen Ismael Esawi
2017 External Supervisor - Doctor of Philosophy Doctorate Full Time Miss Jess Heatlie

Date Role Research Topic Program Degree Type Student Load Student Name
2021 - 2025 Co-Supervisor Response and resistance to cyclin-dependent kinase 4/6 inhibition in prostate cancer Doctor of Philosophy Doctorate Full Time Mr Joshua Thomas Hodgson
2021 - 2025 Principal Supervisor Characterising The Spatial Lipidome of Localised Prostate Cancer by Mass Spectrometry Imaging Doctor of Philosophy Doctorate Full Time Mr Jacob Truong
2020 - 2024 Co-Supervisor Investigating How Fatty Acid Elongation Promotes Prostate Carcinogenesis Doctor of Philosophy Doctorate Full Time Miss Deanna Catherine Miller
2019 - 2023 Principal Supervisor Lipid elongation and its role in prostate cancer Doctor of Philosophy Doctorate Full Time Miss Julia Steele Scott
2019 - 2023 Co-Supervisor Investigating USP2 as a mediator of therapy resistance in lethal prostate cancer Doctor of Philosophy Doctorate Full Time Ms Meiwen Danielle Fang
2018 - 2021 Principal Supervisor Investigating the Contribution of Specific Cancer-Associated Fibroblast Subsets to Colorectal Tumourigenesis Doctor of Philosophy Doctorate Full Time Miss Krystyna Anna Gieniec
2018 - 2024 Principal Supervisor Novel co-targets to improve androgen receptor inhibition in prostate cancer Doctor of Philosophy under a Jointly-awarded Degree Agreement with Doctorate Full Time Miss Josephine Ataa Hinneh
2018 - 2021 Principal Supervisor Targeting fatty acid metabolism in prostate cancer Doctor of Philosophy Doctorate Full Time Miss Chui Yan Mah
2017 - 2021 Co-Supervisor Elucidating the molecular mechanisms underlying androgen-regulated lipid metabolism in prostate cancer Doctor of Philosophy Doctorate Full Time Mr Raj Kumar Shrestha
2016 - 2019 Principal Supervisor Defining the Role of Lipids and Metabolic Factors as Risk Factors for Prostate Cancer Incidence and Aggressiveness Doctor of Philosophy Doctorate Full Time Dr Adel Aref
2016 - 2020 Principal Supervisor Understanding the Role of Androgen Receptor Signalling in Prostate Cancer:
A Lipidomics Approach by MALDI Mass Spectrometry Imaging		 Doctor of Philosophy Doctorate Full Time Mr Shadrack Mulinge Mutuku
2013 - 2016 Principal Supervisor Elucidating the Molecular Action of Synthetic Heat Shock Protein 90 Inhibitors in Prostate Cancer Doctor of Philosophy Doctorate Full Time Miss Heather Krista Armstrong
2013 - 2016 Co-Supervisor The Role of microRNA-194 and microRNA-375 in Prostate Cancer Metastasis Doctor of Philosophy Doctorate Full Time Dr Rajdeep Das
2008 - 2011 Co-Supervisor Investigating Lymphatic Vascular Remodelling During Postnatal Mouse Mammary Gland Morphogenesis Doctor of Philosophy Doctorate Full Time Ms Kelly Louise Betterman
2007 - 2015 Principal Supervisor Combinatorial Targeting of the Androgen Receptor for Prostate Cancer Therapy Doctor of Philosophy Doctorate Full Time Miss Sarah Carter
2006 - 2010 Co-Supervisor The Role of Epigenetic Modifications in Prostate Tumourigenesis Doctor of Philosophy Doctorate Full Time Ms Karen Huiqin Chiam
2004 - 2008 Co-Supervisor Characterisation of a Dominant Negative Androgen Receptor in Prostate Cancer Cells Doctor of Philosophy Doctorate Part Time Dr Margaret Centenera
2004 - 2008 Principal Supervisor Androgen Signalling in Normal and Malignant Breast Epithelial Cells Doctor of Philosophy Doctorate Part Time Ms Amelia Peters
2003 - 2007 Co-Supervisor Targeting the Androgen Receptor as a Therapeutic Strategy for Prostate Cancer Doctor of Philosophy Doctorate Full Time Miss Deborah Marrocco

Date Role Research Topic Location Program Supervision Type Student Load Student Name
2020 - ongoing Co-Supervisor A comprehensive assessment of cancer cell metabolism University of Sydney - Doctorate - Nancy Santiappillai

Date Role Committee Institution Country
2021 - ongoing Chair Australian Prostate Cancer BioResource Executive Committee Australian Prostate Cancer BioResource Australia
2021 - ongoing Chair Research Committee Prostate Cancer Foundation of Australia Australia
2021 - ongoing Board Member National Board of Directors Prostate Cancer Foundation of Australia Australia
2020 - ongoing Member ANZUP Cancer Trials Group, Scientific Advisory Committee Australian and New Zealand Urogenital and Prostate (ANZUP) Australia
2018 - ongoing Chair BROCADE Tissue Access Committee Chair National Breast Cancer Foundation Australia
2017 - ongoing Member Research Advisory Committee Prostate Cancer Foundation of Australia Australia
2016 - ongoing Member Faculty of Health Sciences Research Committee The University of Adelaide Australia
2016 - ongoing Member Genomics Executive Committee South Australian Health and Medical Research Institute Australia
2015 - ongoing Member Appointments Committee South Australian Health and Medical Research Institute Australia
2014 - 2015 Chair School of Medicine Research Committee The University of Adelaide Australia
2013 - ongoing Member ANZUP Cancer Trials Group, Prostate and Translational Sub-Committee Australian and New Zealand Urogenital and Prostate (ANZUP) Australia
2012 - ongoing Convener Australian Prostate Cancer BioResource Executive Committee, Adelaide Node Coordinator Australian Prostate Cancer BioResource Australia
2012 - ongoing Member Australian Prostate Cancer Research - Scientific Member Australian Prostate Cancer Research Australia
2012 - 2015 Member NHMRC Postdoctoral Reference Group National Health and Medical Research Council Australia
2012 - ongoing Member NHMRC Research Translation Faculty National Health and Medical Research Council Australia
2011 - ongoing Member Freemasons Foundation Centre for Men's Health Executive Committee The University of Adelaide Australia
2011 - ongoing Member Movember Global Action Plan for Prostate Cancer - Functional Group Leader Movember Australia
2009 - ongoing Member Postgraduate Coordinator, Adelaide Medical School The University of Adelaide Australia
2009 - ongoing Member Australian Prostate Cancer BioResource Executive Committee Australian Prostate Cancer BioResource Australia
2007 - 2009 Member Institutional Biosafety Committee Institute of Medical and Veterinary Science Australia
2006 - 2013 Member School of Medicine Research Committee The University of Adelaide Australia
2004 - 2009 Member Institutional Biosafety Committee The University of Adelaide Australia
2003 - 2010 Member South Australian Breast Cancer Study Group Executive South Australian Breast Cancer Study Group Australia
2003 - 2005 Board Member Australian Society for Medical Research Australian Society for Medical Research Australia

Date Role Membership Country
2020 - ongoing Member Society for Basic Urological Research United States
2012 - ongoing Member Australian & New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group Australia
2011 - ongoing Member Centre for Personalised Cancer Medicine - University of Adelaide Australia
2006 - ongoing Member Hanson Institute Australia
2006 - ongoing Member Endocrine Society United States
2006 - ongoing Member Endocrine Society of Australia Australia
2004 - ongoing Member South Australian In Vivo Mouse Models Network Australia
2001 - ongoing Member Australian Prostate Cancer Collaboration Australia
1999 - ongoing Member American Association for Cancer Research United States
1995 - ongoing Member Australian Society for Medical Research Australia

Date Title Engagement Type Institution Country
2020 - ongoing Updates in prostate cancer research Public Community Engagement Mount Barker Prostate Cancer Support Group Australia
2020 - ongoing Overloading fats in prostate cancer cells is key to destroying them say researchers Public Community Engagement The Senior (online publication) Australia
2020 - ongoing Radio interview Public Community Engagement 5AA Adelaide Australia
2020 - ongoing Fat can kill cancer cells Public Community Engagement The Adelaide Advertiser (newspaper) Australia
2020 - ongoing Researcher Showcase Discussion Panel (Public Event) Public Community Engagement Cancer Council SA Australia
2019 - ongoing Working Together to Combat a Killer Public Community Engagement The Adelaide Advertiser (newspaper) Australia
2018 - ongoing Taking the Fight to Cancer Public Community Engagement The Adelaide Advertiser (newspaper) -
2018 - ongoing Defining Future Cancer Treatments, promotional video Public Community Engagement The University of Adelaide Australia
2017 - ongoing Lipids, obesity and prostate cancer Public Community Engagement Wealth and Wellbeing SAHMRI initiative launch for Bell Potter Securities Australia
2017 - ongoing Improving diagnosis, treatment and molecular imaging of prostate cancer Public Community Engagement SAHMRI Public Lecture Series - Cancer: Prevention, Diagnosis and Treatment (Public Event) Australia
2017 - ongoing New diagnosis and treatment tools for prostate cancer Public Community Engagement Lions Club Annual Meeting, Adelaide Australia
2017 - ongoing Networking advice for junior scientists Scientific Community Engagement Australian Society for Medical Research, Networking Event Australia
2016 - ongoing New markers for diagnosing prostate cancer Public Community Engagement Prostate Cancer Foundation of Australia Community Conversations (Public Event) Australia
2015 - ongoing Radio interview Public Community Engagement 5AA Adelaide -
2015 - ongoing Radio interview Public Community Engagement ABC Radio Adelaide Australia
2015 - ongoing Lipids, obesity and prostate cancer Public Community Engagement North Shore Prostate Cancer Support Group Australia
2015 - ongoing Prostate hope in pioneer test Public Community Engagement The Adelaide Advertiser (newspaper) Australia
2015 - ongoing Working overseas to build your CV and future career Scientific Community Engagement Australian Society for Medical Research, Networking Event Australia
2015 - ongoing World-first Cancer Research Public Community Engagement The Adelaide Review (newspaper) Australia
2015 - ongoing Radio interview Public Community Engagement ABC Adelaide radio Australia
2015 - ongoing Associate Professor Lisa Butler assembles world class team in bid to develop new biomarkers Public Community Engagement Prostate News (magazine) Australia
2014 - ongoing International research team formed to make impact on clinical care for prostate cancer patients Public Community Engagement The Lead SA (online newspaper) Australia
2014 - ongoing Prostate Team’s $3m Aim Public Community Engagement The Adelaide Advertiser (newspaper) Australia
2014 - ongoing Radio interview Public Community Engagement ABC Radio Adelaide Australia
2014 - ongoing Challenges in prostate cancer research (lay presentation) Public Community Engagement Royal Adelaide Hospital Australia
2014 - ongoing Public laboratory tours Public Community Engagement South Australian Health and Medical Research Institute Australia
2014 - ongoing Regular Consumer Advisory Group Meetings Public Community Engagement The University of Adelaide Australia
2012 - ongoing Radio interview Public Community Engagement 5AA Adelaide Australia
2012 - ongoing Challenges in prostate cancer research - Research Tuesday Public Lecture Series Public Community Engagement The University of Adelaide Australia
2012 - ongoing Towards improved management of breast and prostate cancer Public Community Engagement Cancer Care EXPO (Public Event) Australia
2011 - ongoing Probing the causes and treatment of prostate cancer Public Community Engagement Toshiba Medical presentation to radiology professionals Australia
2008 - ongoing Television news story Public Community Engagement Channel 9 Adelaide Australia

Date Role Editorial Board Name Institution Country
2022 - ongoing Editor Molecular Cancer Research American Association for Cancer Research United States
2020 - ongoing Associate Editor Frontiers in Endocrinology - Systems Endocrinology Frontiers in Endocrinology United States
2019 - ongoing Board Member Journal of the National Cancer Institute Journal of the National Cancer Institute United States
2015 - ongoing Board Member Frontiers in Endocrinology Frontiers in Endocrinology United States
2015 - ongoing Board Member Frontiers in Oncology Frontiers in Oncology United States

Date Title Type Institution Country
2021 - ongoing Grant Review Grant Assessment European Science Foundation -
2020 - ongoing Grant Review Grant Assessment Swiss National Science Foundation Switzerland
2019 - ongoing Grant Review Grant Assessment Australia-India Strategic Research Fund Australia
2018 - ongoing Grant Review Grant Assessment ANZUP Below the Belt Fund Australia
2017 - ongoing Grant Review Grant Assessment Cancer Institute of NSW Australia
2017 - ongoing Grant Review Grant Assessment Prostate Cancer UK United Kingdom
2015 - ongoing Grant Review Panel Grant Assessment Health Research Council of New Zealand New Zealand
2015 - ongoing Research Advisory Committee Grant Assessment Prostate Cancer Foundation of Australia Australia
2015 - ongoing Grant Review Grant Assessment Cure Cancer Australia Australia
2015 - ongoing Grant Review Grant Assessment Cancer Research UK United Kingdom
2013 - ongoing Early Career Fellowships Review Panel Grant Assessment National Breast Cancer Foundation Australia
2012 - ongoing Grant Review Grant Assessment Cancer Council Australia
2012 - ongoing Grant Review Grant Assessment Prostate Cancer Foundation of Australia Australia
2012 - ongoing Grant Review Grant Assessment National Breast Cancer Foundation Australia
2011 - ongoing Grant Review Panel Grant Assessment Cancer Australia Australia
2010 - ongoing Oncology Grant Review Panels Grant Assessment National Health and Medical Research Council Australia
2005 - ongoing Grant Review Grant Assessment National Health and Medical Research Council Australia

Connect With Me

External Profiles

Other Links